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ABSTRACT 
The overall aim of this study was to determine whether host genetic factors 
are associated with resistance to HIV-1 infection in a group of highly exposed 
persistently seronegative sex workers from KwaZulu/Natal, South Africa. 
A cohort of 17 African highly exposed but persistently seronegative (HEPS) 
commercial sex workers (CSW) were identified who had been in sex work for more 
than four years (range between 4-26 years). The women had been followed monthly 
for at least four years as part of HIV-1 prevention programmes (Ramjee, et al. , 1998). 
The overall aim of this study was to identify the frequency of polymorphisms and 
mutations in chemokine genes, chemokine receptors and chemokine receptor promoter 
region which may be associated with HIV-1 resistance and prolonged disease 
progression. Secondly, to determine if the chemokine receptors on CD4 T-cells are 
sufficiently expressed and functional to enable infection. This information will shed 
light on correlates of immunity as influenced by these polymorphisms and this 
knowledge will help in the bigger objective of determining factors influencing disease 
progression as well as the development of an effective HIV-1 vaccine in South Africa. 
The DNA of these women was isolated and the chemokine (SDF1-3 'A) and chemokine 
receptor (CCR5Li32 , CCR5m303 and CCR2b-64I) polymorphisms detected by 
polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) . 
To investigate the effect of polymorphisms in the non-coding region of the CCR5 gene, 
five CCR5 promoter polymorphisms were screened for in the study namely, CCR5 
59029G/A, 59353T/C, 59356C/T, 59402G/A and 59653C/T. Fluorescent hybridization 
probe method was developed to identify these mutations. Peripheral blood mononuclear 
cells (PBMC) were isolated from these women and the proportion of CD4 T-cells 
positive for CCRS and CXCR4 and relative level of expression was determined by flow 
cytometry. 
Lastly, to ascertain whether the chemokine receptors expressed on PBMC surface 
were functional , in vitro infection assays were performed. PBMC from seven HEPS 
women were exposed to six HIV- I viral strains of different subtypes and coreceptor 
usage, included were three R5 , one X4 and two dual tropic (R5/X4) viral isolates. 
No mutations were detected in the CCR5~32 and CCR5m303 variants among the 17 
HEPS samples tested. Two of the 17 samples were heterozygous for the SDFI-3'A, 
resulting in an allelic frequency of 5.8%. This figure was higher than the background 
population figure of 1 % among South Africans (Williamson, et al., 2000). The allelic 
frequency for the CCR2b-64I variant was found to be 15% among HEPS which was 
comparable to the 13% found in the background population (Williamson, et al., 
2000). Two CCR5 promoter polymorphisms (CCR5-59353T/C and CCR5-
59029G/A) associated with disease progression, were found at an elevated frequency 
among the HEPS women, and were always linked. 
There was no difference in the proportions of CD4 T-cells positive for CCR5 and 
CXCR4 receptors between the HEPS women a control group (n = 5) of seronegative 
low risk women. The mean for CD4 T-cells positive for CCR5 was 10.7% and 1.7% 
for HEPS and controls respectively, and for CXCR4 the mean was 89.3% and 83.8% 
in HEPS and controls. The difference in CCR5 and CXCR4 expressed on the surface 
of cells between HEPS and controls was not statistically significant (p=0.117 and 
p=0.964 respectively) indicating normal expression levels among the HEPS 
population. 
All viral strains irrespective of subtype or coreceptor usage replicated in the PBMC of 
all HEPS samples tested (n=7), indicating that the chemokine receptors were 
sufficiently expressed on PBMC and that they were functional. 
In conclusion, none of the well characterised mutations in the CCR5 gene associated 
with resistance were identified in this study population. 
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In addition, CCR5 and CXCR4 expression on the surface of cells was 
demonstrated to be sufficient and functional as cells from all HEPS samples tested 
were found to be susceptible to infection with all viral strains tested. An elevated 
frequency of the SDF1-3'A variant and certain CCR5 promoter polymorphisms 
was observed. However, the mechanism of how this variant may confer resistance 
is puzzling as sexually transmitted IDV-1 strains utilize the CCR5 receptor and not 
CXCR4. 
Further work needs to be done to ascertain the background frequencies of the 
SDF-1 and promoter polymorphisms in South Africa, and their role in IDV-1 
pathogenesis. The fluorescent hybridization probe method developed to screen for 
CCR5 promoter polymorphisms was found to be reliable, when compared to other 
conventional methods used for point mutation detection such as PCR-RFLP and 
sequencing. This method was also found to be easier and faster. 
This is the first study on HEPS in South Africa, it is hoped that correlates of 
immunity as influenced by the genetic variants studied here will shed light with 
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1.1.1 General introduction 
CHAPTER 1 
INTRODUCTION 
One of the major obstacles in the development of an HIV- 1 vaccine is a lack of
 
understanding regarding the mechanisms of natural protection against HIV-1
 
infection. One approach to identify factors related to protection, has involved the
 
intensive study of cohorts of high-risk individuals who remain uninfected despite
 
repeated exposure to HIV- I, referred to as "nature's experiment" (Shearer, et al.,
 
1996). Cohorts studied include commercial sex workers (Rowland-Jones, et al., 
1995), sex partners of HIV-1 infected individuals (Mazzoli, et al., 1997) and,
 
infants born to HIV-1 infected mothers (Clerici, et al. , 1993). Of these different
 
groups, commercial sex workers (CSW) represent a particularly compelling
 
population in which to study mechanisms of resistance to HIV-1 infection. Unlike
 
new horns of infected mothers, or HIV -1 discordant couples, who sustain multiple
 
exposures to the same viral variant, commercial sex workers are likely to
 
experience a variety of high-risk exposures to a multitude of HIV-1 variants over a
 
prolonged period of time (Beyer, et al., 1999). Studying these HIV-1 resistant
 
cohorts will shed light on which host genetic factors and immunological parameters
 
are implicated in preventing HIV- I infection. 
It is likely that highly exposed but persistently seronegative (HEPS) individuals are
 
protected from HIV-1 infection by a number of factors. Host genetic factors like
 
polymorphisms in the chemokine receptor genes or their ligands play a role in
 
resistance. An association between human leukocyte antigen (HLA) and resistance
 
to infection and fo disease has also been described. Immunological factors like
 
cytotoxic T-lymphocyte (CTL) responses, antibody responses are also thought to
 
confer resistance to HIV- I infection or delay disease progression. 
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In most cases, resistance to HIV- I infection is probably a consequence of a 
combination of these and more, as yet undiscovered factors. There is currently no data 
on factors conferring resistance to infection in South Africa populations. This review 
will focus on host genetic mutations, which contribute to resistance to infection or 
disease. Immunological correlates of immunity will be covered briefly. 
1.1.2 Chemokine receptors as IDV-1 coreceptors 
The entry of HIV- I into human cells has been demonstrated to depend on CD4 receptor 
molecules on the cell surface (Dalgleish, et al., 1984). However, the CD4 molecule 
alone is not sufficient to render cells susceptible to HIV-I infection (Clapham, et al., 
1991 and Dragic, et al., 1996) and a coreceptor is required by the virus . Two major 
HIV-1 coreceptors have been identified, CCRS and CXCR4, both of which are 
chemokine receptors. These receptors are members of the seven transmembrane G-
protein coupled family (Raport, et al., 1996) and are important components of the 
immune response to inflammation and infection. 
Transformed T-cell lines, such as MT-2 cells, have proven very useful in phenotyping 
viruses as these cells express high levels of CXCR4, but do not express CCRS. Viruses 
that fail to form syncytia when grown in MT-2 cells have been referred to as non-
syncytium inducing (NSI) and because of their ability to infect macrophages have also 
been referred to as macrophage tropic (M-tropic) or slow-low in reference to their 
replication kinetics in culture (Feng, et al., 1996). CCRS is a coreceptor for non-
syncytium inducing (NSI) HIV- I strains in vitro, also classified as RS viral strains 
(Berger, et al., 1998). Whereas, viruses able to infect T-cell lines have been referred to 
as T-tropic, syncytium-inducing (SI), or rapid-high (RH) (Fenyo, et al., 1996). The 
CXCR4 chemokine receptor is used by syncytium inducing (SI) HIV-1 viral strains in 
vitro (Deng, et al., 1996), these viral strains are also classified as X4 (Berger, et al., 
1998). HIV- I infected patients harbour predominantly RS HIV-I isolates during early 
stages of infection, but accumulate increasing amounts of X4 viral strains just before 
accelerated T-cell depletion and progression to AIDS (Smith, et al., 1997). This tropic 
transition indicates that viral adaptation from CCR5 to CXCR4 receptor use may be a 
key in progression to AIDS (Deng, et al., 1996). However this switch does not occur in 
all patients. 
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HIV-1 subtype-C HIV -1 viral isolates, the predominant subtype in South Africa, for 
reasons that are still unclear predominantly use CCR5 coreceptor with rare reported 
usage of CXCR4 (Cecilia, et al., 2000). 
Chemokines (soluble chemical messengers that attract white blood cells to inflamed 
areas) and their receptors are critical components of HIV-1 infection. Chemokines are 
70-90 amino acids in length and can be subdivided into two groups, the a.-chemokines, 
which contain a single amino acid between the first and second cysteine residues, 
whose function is to activate neutrophils (D' Souza, et al., 1996). Stromal derived factor 
(SDF-1) is an example of an a.-chemokine and is also a ligand to the CXCR4 a.-
chemokine receptor. 
The P-chemokines have adjacent cysteine residues, and they generally activate 
monocytes, lymphocytes, basophils and eosinophils. RANTES (regulated upon 
activation normal T-cell expressed and secreted), macrophage inflammatory protein 
(MIP-la. and MIP-lP) are P-chemokines and act as ligands to the P-chemokine receptor 
CCR5 (D'Souza, et al., 1996). Various cytokines produced by CD8 T-cells can 
suppress HIV-1 replication (Barker, et al. , 1998). The P-chemokines RANTES, MIP-la. 
and MIP-1 p can block R5 tropic viruses from replicating in peripheral blood 
mononuclear cells (PBMC) and CD4 cells (Cocchi, et al. , 1995). 
In addition to CCR5 and CXCR4, nine other chemokine receptors have been shown to 
support the cellular entry of one or more virus strains in vitro. These include, CCR2b, 
CCR3, CCR8, GPRl, GPR15 (Bob), STRL33 (Bonzo/TYMSTR), US38, V28 
(CX3CR1) and ChemR23 (Choe, et al., 1996, Doranz, et al., 1996, Samsom, et al., 
1997 and Deng, et al. , 1997). CCR5 is also used by HIV-2 and SIV isolates although 
CXCR4 is only used by HIV-I. BOB and Bonzo are used by SIV and HIV-2 isolates 
but only rarely by HIV-1 isolates. The in vitro significance of these minor coreceptors 
in HIV-1 infection still remains uncertain (Zhang and Moore, 1999). Table 1 depicts 
chemokine receptors and their natural ligands, their expression patterns and viral usage. 
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Table I : Chemokine receptor family members' known function as receptors in HIV and SIV entry 
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1. 1. 3 Ligands and chemokine receptor polymorphisms associated with 
HIV-1 resistance to infection 
·--·-----
The recent discovery of several mutations and polymorphisms in the genes of the HIV-
I chemokine coreceptors (D'Souza, et al., 1996) has led to a greater understanding of 
the host genetic factors that play an important role in susceptibility to HIV- I infection 
and in the rate of disease progression (Dean, et al., 1996). The most studied among the 
HIV/AIDS resistance mutations is the 32bp nucleotide deletion in the CCR5 gene. The 
mutation results in truncation of the CCR5 protein and abrogation of its HIV -1 
coreceptor function (Liu, et al., 1996 and Samsom, et al., 1996), including its 
chemokine signaling function. CD4 T-cells from these individuals were highly resistant 
in vitro to the entry of primary M-tropic (RS) HIV-I isolates but readily infectable with 
viruses adapted to grow in T-cell lines (Paxton, et al., 1996). The homozygosity for 
CCR5f..32 is highly protective against HIV-I infection, though the protection is not 
absolute (O 'Brien, et al., 1997). Individuals who are heterozygous for the CCR5f..32 
allele have been shown to progress more slowly to AIDS than wild-type homozygous 
individuals (Husman, et al., 1999), suggesting that CCR5 expression levels may be 
altered in these individuals, and that this affects HIV-I replication in vivo. 
Another CCR5 gene variant was identified which results from a single base 
substitution. A (T-to-A) substitution at position 303 in the open reading frame (ORF) of 
the CCR5 gene, introduces a premature stop codon (Quillent, et al., 1998). 
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This rare variant, CCR5m303 leads to the lack of expression of a functional CCR5 
protein and abrogation of its HIV-1 coreceptor function . This variant, was identified 
in less than 1 % Caucasians (Quillent, et al., 1998) and has never been identified in 
Africans (Williamson, et al., 2000). Individuals with CCR5m303/~32 genotype are 
resistant to infection and it is assumed that CCR5m303 has similar effects to 
CCR5~32 on delaying disease progression. 
The CCR5 gene is organised into four exons and two intrans. Exons 2 and 3 are not 
interrupted by an intron. Exon 4 and portions off exon 3 are shared by all isoforms. 
Exon 4 contains the open reading frame (Fig 1.1). 
2 3 4 ORF 
Fig. 1.1 : A schematic representation of the genomic organisation of the CCR5 (Mummidi et al., 
1998). Open boxes represents exons or open reading frames (ORF), dashed lines represents 
connecting introns. Exons are numbered at the upper left of corresponding box . 
Strama! derived factor (SDF-1) is the principal ligand for CXCR4, a coreceptor 
with CD4 for T-tropic (X4) cell line HIV-1 isolates. The SDF1-3'A variant is a 
result of base substitution in the 3 '-untranslated region (UTR) of SDF-1 gene and 
this G-to-A substitution has been showP. to be associated with delayed disease 
progression in HIV-1 infection (Winkler, et al., 1998). The protective effect of the 
SDF 1-3 'A variant is recessive as it is observed only in homozygotes (SDF 1-
3 'N3 'A) allele carriers (Winkler, et al, . 1998), no difference is apparent in this 
respect between wild type (SDF-1) and heterozygotous (SDFI/3'A) individuals 
(Voevodin, et al. , 1999). However, other studies have shown contradictory effects 
of the SDF1-3'A variant. The SDF1-3'A variant has been shown to accelerate 
disease progression among seroconverters (Brambilla, et al., 2000). The SDF 1-3 'A 
variant is wide spread in all populations, the SDF 1-3 'A allelic frequency in 
Caucasians is 21.1 % compared to 5.7% in African Americans (Winkler, et al., 
1998). 
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A G-to-A nucleotide substitution has been identified at position 190 of CCR2 that 
substitutes the CCR2 wild type amino acid residue valine at position 64 with 
isoleucine. This change is located within the first transmembrane domain of the 
CCR2 receptor and results in a CCR2b-64I variant (Smith, et al., 1997). This single 
base substitution was associated with postponed development of AIDS by 2-4 
years, but the gene variant was not associated with primary protection against HIV-
I infection (Smith, et al., 1997). 
The CCR2b-64 I variant is located in a transmembrane domain of the CCR2 protein, 
which is not a part of the HIV-I binding site. The protection mechanism is thought 
to be indirect, since most HIV-1 isolates do not use CCR2 as their coreceptor. In 
this respect, an interesting hypothesis has been suggested that CCR2b-64I 1s 
tracking another polymorphism in the promoter region (Samson, et al., 1996). 
Kostrikis et al., ( 1998) identified a C-to-T base substitution at position 59653, 
(GenBank Accession Number U95626), in the CCR5 promoter region that was in 
linkage disequilibrium with CCR2b-64I. The human CCR5 and CCR2 chemokine 
receptors, are tightly linked on chromsome 3p2 l-22 (Dean et al., 1996). The 
CCR2b-64I allelic frequency of 15 .1% in African Americans is higher than 9.8% 
observed in Caucasians (Kostrikis, et al., 1998). 
1.1.4 CCRS promoter polymorphisms and their role in HIV-1 
pathogenesis 
Recognition of the heterogeneity existing in the regulatory region of the CCR5 gene 
(Mummidi, et al., 1998) has lead to speculation about the influence of regulatory 
region polymorphisms on CCR5 receptor expression and consequently on the rate 
of HIV-1 disease progression (Smith, et al., 1997). Polymorphisms in the regulatory 
region of the CCR5 gene has been shown to influence HIV -1 vertical transmission, 
Kostrikis, et al., ( 1999) identified a base substitution in the promoter region of the 
CCR5 gene (CCR5-59356-T) that was prevalent in the African American 
population 20.6% compared to 3.4% in Caucasians and Hispanics (5.6%). 
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Six hundred and sixty seven ( 667) infants born to HIV- I infected mothers not 
treated with AZT (zidovudine) during pregnancy were studied, three populations 
were investigated Hispanics (n=65) Caucasians (n=492) and African Americans 
(n=691). In all population groups the CCR5-59356T variant was found to be 
associated with increased HIV- I transmission from mother to child. This is the only 
study showing an effect on transmission due to a promoter polymorphism. 
A CCR5 promoter polymorphism, a G-to-A substitution at position 59029 
(GenBank Accession Number U95626) has been associated with altered rates of 
HIV-1 disease progression (Biti, et al., 1997). The CCR5-59029G allele, which is 
associated with slower disease progression in HIV-1 positive homozygotes 
compared with CCR5-59029A homozygotes (McDermott, et al., 1998), is more 
common than all other variants found to date . Unlike CCR5~32 which is found 
mainly in Caucasians, CCR5-59029G is present in high frequencies in all racial 
groups (McDermott, et al., 1998). Thus, it is likely that this polymorphism affects 
HIV- I pathogenesis worldwide. HIV- I seroconverters who were homozygous for 
CCR5-59029A and lacking CCR5~32 and CCR2b-64I mutations were found to 
progress to AIDS on average 3.8 years more rapidly than those who were 
homozygous for CCR5-59029G allele (McDermott, et al., 1998). 
A C-to-T polymorphism at position 59353 was also identified, with the CCR5-
59353T allele associated with delayed disease progression. The CCR5-59353C 
variant occurring with the CCR5-59029A variant in six out of six patient samples 
sequenced by McDermott, et al., (1998). CCR5-59353C as well as CCR5-59029A 
were under represented in HIV-1 infected long term non-progressors (Clegg, et al. , 
2000) . This indicates that there is a delay in disease progress ion in HIV-1 infected 
individuals carrying CCR5-59353T alleles. 
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A differential effect on promoter activity between CCR5-59029A/CCR5-59353C 
and CCR5-59029G/CCR5-59353T has been demonstrated in vitro acetlytransferase 
(CAT) reporter gene constructs containing the CCR5-59029A/CCR5-59353C 
polymorphisms resulted in 45% more activation than constructs containing the 
CCR5-59029G/CCR5-59353T polymorphisms (Clegg, et al., 1999). 
Increased promoter activity such as that associated with CCR5-59029A/CCR5-
59353C could result in increased levels of CCR5 mRNA production and cell 
surface expression of the CCR5 receptor (Clegg, et al., 1999), and thus affect 
disease progression. CCR5-59402G/ A variant has been identified though its effect 
of HIV-1 and disease progression it not known (Mummidi, et al., 1998). 
Table 2 depicts a summary of all chemokine, chemokine receptor mutations and 
polymorphisms in the non-coding region of CCR5 and their effects of HIV-1 
pathogenesis. 
Table 2: Host genetic variants and their role in HIV-I pathogenesis 
Gene variant Effect on HIV-1 pathogenesis 
Chemokine 













Accelerates disease progression 
Delays disease progression 
Protects against HIV -1 infection 
(homozygote) and delays disease progression 
(heterozygote) 
Delays disease progression and protects 
against HIV- I transmission when linked with 
CCR5Ll32 
Slows down disease progression 
Accelerates disease progression 
Delays disease progression 
Protects against HIV-1 vertical transmission 
Function unknown 




Winkler, et al., 1998 
Brambila, et al., 2000 
McDermott, et al. , 2000 
Liu, et al., 1996 
Quillent, et al., 1998 
Smith, et al., 1997 
Mummidi, et al. , 1998 
McDermott, et al., 1998 
Kostrikis, et al., 1999 
Mummidi, et al. , 1998 
Samson, et al., 1997 
1.1. 5 Chemokine receptor expression levels and CD4 T-cell 
susceptibility 
The two major HIV-1 coreceptors, CCRS and CXCR4, have been shown to be 
differentially expressed in different sub-populations of CD4 T-cells. CCRS is 
mainly expressed on memory and activated T-cells as marked by their high 
expression of CD4SRO and low expression of CD4SRA, in contrast, CXCR4 is 
expressed highly by na'ive and resting cells as marked by their high expression on 
CD4S (Ostrowski, et al., 1997). Because na'ive cells are resting cells, it is therefore 
conceivable that most CD4 T-cells expressing CXCR4 are resting cells and are not 
permissive for the complete viral life cycle and active viral replication. The 
availability of target cells for viral replication, i.e. activated cells with appropriate 
viral receptors, may play a crucial role in viral dynamics and pathogenesis of AIDS. 
Ostrowski, et al., (1997) found that the heightened state of cellular activation in 
HIV-1 infected individuals is associated with CCRS up-regulation and CXCR4 
down-regulation on CD4 T-cells, and that this milieu may favour the propagation of 
macrophage-tropic (RS) viruses. Coreceptor expression levels were found to 
correlate with the levels of cellular activation in vivo. Lower expression levels of 
CCRS and higher expression of CXCR4 on CD4 T-cells was found to correlate with 
early disease state, while, lower expression levels of CXCR4 and higher expression 
of CCRS on CD4 T-cells correlated with advanced disease stage (Ostrowski, et al., 
1997). 
Expression levels are highly variable on cells from individuals with the wild type 
CCRS genotype (Moore, et al., 1997), and there seems to be a correlation between 
the level of expression and in vitro infectability with RS tropic HIV-1 strains 
(Reynes, et al., 2000). Individuals carrying the CCRSL\32 allele and HEPS we 
found to have CD4 T-cells with reduced infectability by RS HIV-1 strains. This 
reduction in in vitro infection by CD4 T-cells was attributed to low CCRS 
expression levels and may be associated with protection against sexual transmission 
ofHIV-1 (Paxton, et al., 1998). 
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for both genotypic groups (CCRS and CCR.5632), the percentages of CCRS-
expressing cells were higher in the HIY- 1 infected group than in the uninfected group. 
CCRS expression was shown to increase with progression of disease, possibly as a 
consequence of continuous immune ,1ctivalion associated with HIV-1 infection 
(Husman, et al, 1999). 
1.1 . G llum:rn leukocyte antigens (HLA) associated ·w ith lHV-1 resistance. 
Certain HLA phenotypes have been found to be prevalent in HEPS CSW. An 
increased frequency of the HLA-18 and I-ILA-Al 1 phenotype v,1as found in HEPS in 
Thailand (Beyrer, el al., 1999) . Interestingly I-ILA- 18 was also the class l allele 
associated with resistance to HIY-1 infection in the East ACrican HEPS (Plummer, et 
al, 1993). In aclclition, HLA-B 18 has been reported to be associated with slov,1 or non-
progression to /\JDS in l-JlY- 1 i11lcctecl Caucasians (Kaslow, el ul. I 99G). 
111 ,1 study clone in Gambia, the most prevalent HL!\ phenotype among the HEPS 
population was HLA-835, which was found in higher frequencies in HEPS compared 
to I llY- 1 infected individuals (Rowland -Jones, et al., 1995). The [-ILA-A6082 and 
l lLA-B J 8 phenotypes were found Lo have the strongest protective activity in HEPS 
individuals in Nairobi, Kenya (Rowland-Jones, et al., 1998). The I-ILA system docs 
play a significant role in I-UV-1 resistance as indicated in these diverse studies done 
around the world. Jn a preliminary study clone on the HEPS women from the sex 
worker cohort in KwaZulu/Natal shov-;ed a cluslering of HLJ\.-A24 compared to 
backgrou nd frequencies in women from the same region of KwaZulu/Natal (Dr. AJ 
Puren, XIlI international AJDS, 2000). Whether A24 is a true resistance marker 
remains to be determined. 
1 . 1 . 7 Immunological responses associated ·w itb IIP/-1 resistance 
Globa lly, over 72% of HlV-1 infections occur in lhe developirw world with b ' 
heterosexual transmission accounting fo r most infcclions in these regions (UNA1DS , 
December 2000). As most HIV-1 transmission is sexual, immune responses in the 
genital mucosa may be important in mediating protection against HIV-] infection 
l l 
Husman, et al., (1999) found that HIV-I infected individuals carrying the CCR5 
allele had higher percentages of CCR5-expressing CD4 T-cells as compared with 
HIV-I infected individuals carrying the (CCR5ti32) heterozygote allele. 
For both genotypic groups (CCR5 and CCR5ti32), the percentages of CCR5-
expressing cells were higher in the HIV -1 infected group than in the uninfected 
group. CCR5 expression was shown to increase with progression of disease, 
possibly as a consequence of continuous immune activation associated with HIV-I 
infection (Husman, et al., 1999). 
1.1. 6 Human leukocyte antigens (HLA) associated with HIV-1 resistance. 
Certain HLA phenotypes have been found to be prevalent in HEPS CSW. An increased 
frequency of the HLA-18 and HLA-Al 1 phenotype was found in HEPS in Thailand 
(Beyrer, et al., 1999). Interestingly HLA-18 was also the class I allele associated with 
resistance to HIV-I infection in the East African HEPS (Plummer, et al., 1993). In 
addition, HLA-BI8 has been reported to be associated with slow or non-progression to 
AIDS in HIV-I infected Caucasians (Kaslow, et al. 1996). 
In a study done in Gambia, the most prevalent HLA phenotype among the HEPS 
population was HLA-B35, which was found in higher frequencies in HEPS compared to 
HIV-I infected individuals (Rowland-Jones, et al., 1995). The HLA-A6082 and HLA-
B 18 phenotypes were found to have the strongest protective activity in HEPS 
individuals in Nairobi, Kenya (Rowland-Jones, et al., 1998). The HLA system does play 
a significant role in HIV- I resistance as indicated in these diverse studies done around 
the world. In a preliminary study done on the HEPS women from the sex worker cohort 
in KwaZulu/Natal showed a clustering of HLA-A24 compared to background 
frequencies in women from the same region of KwaZulu/Natal (Dr. A.J Puren, XIII 
International AIDS, 2000). Whether A24 is a true resistance marker remains to be 
determined. 
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(Kaul, et al., 1999). Several HIV- I specific immune responses have been associated 
with resistance to infection, including cytotoxic T-lymphocyte responses (CTL), T-
helper responses and mucosa! IgA responses. Major histocompatibility complex (MHC) 
alleles determine the molecular targets of the cellular immune response in a given host, 
and immunological resistance in these cohorts was therefore also linked to increased 
frequency of certain HLA allele (as described in 1.1.6). 
1.1. 7 a) Cellular immune responses 
There have been two African cohorts which have been well characterised with respect 
to their immune responses to HIV-1 infection, one in Gambia and one in Kenya. In both 
cohorts systemic and local CTL responses have been demonstrated. In a study done in 
Gambia on HEPS commercial sex workers (CSW) with HLA-B35, three out of six 
HEPS women generated CTL responses to most of the specific HIV-I peptides tested 
(nef, pol, p24 and pl 7) compared to none of the 12 seronegative individuals (Rowland-
Jones, et al., 1995). The strongest response was generated towards the HJV-1 pol 
peptide, a peptide located near to the active site of reverse transcriptase, and to a highly 
conserved peptide in nef which is conserved between HJV-1 and HIV-2. The HEPS in 
Kenya recognize many CTL epitopes presumably because, these women are exposed to 
multiple subtypes of HJV-1 (Rowland-Jones, et al., 1998). 
HIV-1 specific cytotoxic T-lymphocytes are present in the genital tract of most HIV-1 
infected women (Musey, et al., 1997). HEPS CSW in a study done in Kenya had 69% 
HIV -1 specific CD8 T-cell response in their cervix and no CTL responses were 
detected in HJV-1 uninfected controls (Kaul, et al., 2000). 
Detection of HIV- I specific CTL in HEPS suggest that one of the mechanisms of 
resistance is through the induction of specific CTL response, by the class I-MHC (Goh, 
et al. , 1999). Of interest is that Kenyan sex workers who left sex work for a period of 
time, became infected once they resumed sex work (Dr. Sarah Roland-Jones, XIII 
International AIDS, 2000). This raises questions on why these women were no longer 
resistant, and implies non-host related factors conferring resistance. 
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Detection of HIV-1 specific CTL in HEPS suggest that one of the mechanisms of 
resistance is through the induction of specific CTL response, by the class I-MHC 
(Goh, et al., 1999). Of interest is that Kenyan sex wokers who left sex work for a 
period of time, became infected once they resumed sex work (Dr. Sarah Roland-
Jones, XIII International AIDS, 2000). This raises questions on why these women 
were no longer resistant, and implies non-host related factors conferring resistance. 
In addition to CTL responses, T-helper responses have also been demonstrated in 
exposed uninfected individuals. Systemic T-helper lymphocyte responses to HIV-1 
envelope peptides were present in 11 out of 20 (55%) exposed uninfected sex 
workers, 4 out of 18 (22%) infected women, and one out of 25 (4%) lower risk 
women in a study done in Kenya (Kaul, et al., 1999). 
1.1. 7 b) Antibody response 
HIV -1 infection in humans leads to an antibody response directed against most of 
the viral structural antigens, and of particular interest are neutralising antibodies 
directed against HIV-1 envelope antigens, namely, the precursor gp-160 and its 
cleavage products, gp-120 and gp-41 (Brown, et al., 1999). The major class of 
immunologlobulin is IgG which circulates in blood and is also present in mucosal 
exudates. The secretory form is IgA which is found in mucosa. HIV-specific IgA is 
made by immunocytes in the cervical mucosa and fallopian tubes and represents 
another possible mechanism of immune resistance to HIV-1 infection. 
HEPS are consistently HIV-1/2 IgG seronegative. However a number of studies 
have shown that IgA antibodies against HIV proteins can be detected. Mazzoli, et 
al., (1997) observed HIV-1 specific IgA responses, but not IgG, in serum, urine and 
vaginal washes of the 15 HIV -1 uninfected heterosexual partners of HIV -1 infected 
individuals. In a study done in Kenya, IgA was detected in higher levels in HEPS 
than in HIV-1 infected women and HIV-1 uninfected women (Kaul, et al., 1999). 
The same results were obtained from a study on HEPS CSW in Thailand where anti 
gp 160 IgA was detected in six of 13 women tested (Beyrer, et al., 1999). 
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However, no IgA response was detected to gp 120. This data indicates the presence 
of HIV -1 envelope specific mucosal IgA responses in HEPS, consistent with the 
finding in a discordant couple cohort (Mazzoli, et al., 1997). 
The role of IgA in HIV-1 resistance is demonstrated by the prevalence of these 
antibodies in HEPS cohorts. There were higher levels of IgA (76%) detected in 
HEPS than in HIV-1 infected women (26%) and HIV-1 uninfected women ( 11 % ) 
tested in Kenya, which indicates the protective role played by the IgA antibodies in 
the genital tract of HEPS individuals (Kaul, et al., 1999). HIV-1 specific IgA with 
neutralizing activity were detected in higher frequency (73%) in plasma and vaginal 
fluid (79%) of HEPS (Devito, et al., 2000). The prevalence of IgG detected in sera 
was in direct opposite to the prevalence of IgA detected in vaginal washings. None 
of the 21 HEPS tested had IgG and all of the 19 HIV -1 infected women had IgG 
antibodies in their sera (Kaul, et al., 1999). 
HIV-1 specific IgA but not IgG was detected in vaginal wash samples from HIV-1 
exposed seronegative individuals, whereas both IgA and IgG were observed in 
HIV-1 seropositive individuals (Rowland-Jones, et al., 1998). The prevalence of 
HIV-1 specific IgA was found to be higher (82%) in HEPS than in HIV-1 infected 
individuals (1 % ), whereas in HIV-1 infected individuals the levels of IgG were 
higher than the levels of IgA (Rowland-Jones, et al., 1998). This combined data 
suggest that HIV-1 specific IgA plays a crucial role in HIV -1 resistance. 
1.1.8 Project motivation 
This is the first study to investigate host factors which may confer immunity to 
infection with HIV -1 in a South African population of highly exposed but 
persistently seronegative (HEPS) commercial sex workers. The overall aim of this 
study is to identify the frequency of polymorphisms and mutations in chemokine 
genes, chemokine receptors and chemokine receptor promoter region which may be 
associated with HIV-1 resistance and prolonged disease progression. Secondly, to 
determine if the chemokine receptors on CD4 T-cells are sufficiently expressed and 
functional. 
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This information will shed light on correlates of immunity as influenced by these 
polymorphisms and this knowledge will help in the bigger objective of determining 
factors influencing disease progression as well as the development of an effective 
HIV-1 vaccine in South Africa. 
This study was done on 17 HEPS commercial sex workers from a closely monitored 
cohort based in KwaZulu/Natal (G.Ramjee, MRC). This group of women have been 
participating in a prevention programme and were screened monthly for HIV-1 for 
four years. Commercial sex workers make a compelling group for such a study as 
they are multiply exposed to HIV-1 and are also exposed to more than one HIV-1 
strain. However, the limitation in looking at this group is that results obtained can 
not be accurately extrapolated to the normal population for the very reasons given 
above. It is possible that multiple exposures to multiple partners prime the immune 
system differently compared to individuals with exposure to a restricted number of 
partners. 
Resistance is almost certainly multifactorial, and associated with both host and 
immune factors. In this project only the host genetic factors associated with HIV-1 
resistance were investigated. 
Polymorphisms in the chemokine (SDF 1-3 'A) and chemokine receptors (CCR5~32, 
CCR5m303 and CCR2b-64I) are known to be associated with decreased disease 
progression. Only the loss of function of CCR5 due to 632 and m303 have been 
associated with resistance. However, in addition to investigating the frequency of 
mutations known to result in abrogation of CCR5, it is relevant to investigate 
frequency of polymorphisms which affect disease progression as the mechanism 
governing resistance to disease may also decrease the susceptibility to infection. In 
addition, it has been shown that individuals with low levels of chemokine receptors 
on their T-cells may be less susceptible to infection. 
In order to address these questions we determined the proportion of CD4 T-cells 
positive for chemokine receptors (CCR5 and CXCR4) and the expression levels of 
these receptors on CD T:-cells by flowcytometry. 
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We also tested peripheral blood mononuclear cells (PBMC) susceptibility to 
infection using different HIV-1 sub-types in vitro. Lastly, a number of studies have 
shown that polymorphisms in the non-coding region of the CCR5 gene affect levels 
of expression and therefore, possibly, susceptibility to infection. In this study, 
HEPS samples were screened for the presence of four (CCR5-59029G/A, CCR5-
59353T/C, CCR5-59402G/A and CCR5-59653C/T) variants. To do this, a novel 
method was developed using fluorescent hybridization probes on the LightCycler 
(Roche), results obtained were compared to known methods of genotyping like 
PCR-RFLP and sequencing. 
These polymorphisms have never been investigated in South African HEPS, hence 
their role in HIV-1 resistance if any has never been determined in this country. 
This study is part of a multicentre initiative between the (MRC, S.A) in Durban and 
other research institutions within South Africa. Dr. G. Ramjee and Prof. SS Abdool 
Karim (MRC) established and run the sex work cohort. Dr. Adrian Puren is 
investigating the relationship between the Human Leukocyte Antigen (HLA) and 
resistance and Dr. Clive Gray is studying the immunology of the sex work cohort, 
both are from the National Institute for Virology (NIV, SA). 
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2.1) INTRODUCTION 
The role played by chemokines and their receptors in the pathogenesis of AIDS is a 
rapidly expanding field. One of the most interesting findings in this field has been the 
discovery of mutations in genes coding for chemokine receptors, and their ligands, 
which confer resistance to HIV-1 infection and AIDS (Voevodin, et al., 1999). In 
addition, non-coding polymorphisms in the CCR5 promoter region have also been 
found to influence transmission and disease progression (Chapter 4). 
Since 1995, chemokines and their receptors have been shown to be determinants in the 
infection process inasmuch as they represent competitive inhibitors and coreceptors for 
HIV-1 infection, respectively (Desouza, et al., 1996). The chemokine receptors CCR5, 
and CCR2b, and SDF-1 , the ligand of CXCR4 influence HIV-1 disease progression 
(Samsom, et al., 1996). 
The most studied among HIV/ AIDS resistance mutations is a 32bp deletion in the 
CCR5 gene, referred to as CCRS.6.32. This mutation results in truncation of the CCR5 
protein and abrogation of its HIV-1 coreceptor function (Liu, et al., 1996). The 
defective CCRS gene (CCRS.6.32) affords near total protection against HIV-1 infection 
in individuals homozygous for the deletion (Biti, et al., 1997), and delays the 
development of AIDS in HIV-1 infected individuals who are heterozygous for the 
deletion (Dean, et al., 1996). The CCRS.6.32 mutation is found in the Caucasian 
population at an allelic frequency of 10-20% and is extremely rare in people of African 
or Asian ancestry (Williamson, et al., 2000 and Martison, et al., 2000). 
A single base substitution (T-to-A) at position 303 of the CCR5 gene open reading 
frame (ORF), referred to as CCR5-m303 (Quillent, et al. , 1998) introduces a premature 
stop codon in a coding sequence of the first extracellular loop of CCR5 protein. This 
rare variant leads to the lack of expression of a functional CCR5 protein and is thus 
likely to delay development of AIDS, as has been shown for the CCR5.6.32 mutation 
(Dean, et al., 1996). 
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This mutation was identified at a frequency of less than 1 % in the South African 
Caucasian population and has never been identified in people of African ancestry 
(Williamson, et al., 2000). 
Stromal derived factor (SDF-1) is the principal ligand for CXCR4, a coreceptor for X4 
HIV-1 strains. The SDF1-3'A variant is a result of a single base substitution (G-to-A) in 
the 3'untranslated region (UTR) of SDF-1 gene. SDF1-3'A variant affects the rate of 
progression to AIDS in individuals who are homozygous (SDF1-3'N3'A) for this 
variant (Winkler, et al., 1998). The proposed hypothesis for SDF 1-3 'N3 'A mechanism 
of action, is that it up-regulates the quantity of SDF-1 protein available to bind CXCR4 
and thus stems the appearance of late stage X4 HIV-1 strains (Winkler, et al., 1998). 
However recent studies have shown that there is a correlation between SDFl-3 'N3 'A 
genotype and accelerated disease progression after onset of AIDS (Brambilla, et al., 
2000). 
The SDFl-3 'A variant is wide spread and has being identified in all the populations in 
the world. This variant exists at different allelic frequencies in the different parts of the 
world, influenced by ethnic and racial background of the population. In South Africa the 
allelic frequency of SDF1-3'A is 1.0% among the African population and 20% among 
the Caucasian population (Williamson, et al., 2000), and in North America the allelic 
frequency is 39% among the Caucasian population and 15% among the African 
American population (Huang, et al., 1996). 
The CCR2b-64I variant has a G-to-A substitution at position 190 in the CCR2 gene that 
substitutes the CCR2 wild type amino acid residue valine at position 64 with isoleucine, 
a conservative change located within the first transmembrane domain of the CCR2 
(Smith, et al., 1997). The amino acid substitution is located in a transmembrane domain 
of the CCR2b receptor which is not a part of the HIV-1 binding site, suggesting that the 
effect of this polymorphism is probably by some indirect mechanism (Smith, et al., 
1997). The CCR2b-64I polymorphism does not result in protection from HIV-1 
infection, but, has been reported to significantly prolong HIV-1 disease progression to 
AIDS in CCR2b-64I carriers (Smith, et al. , 1997). 
19 
The CCR2b-64I variant is found in higher allelic frequencies in people of African 
ancestry, with an allelic frequency of 13.3% in Africans compared to 7.2% of 
Caucasians in South Africa (Williamson, et al., 2000). The allelic frequency in African 
Americans is 27.7% compared to 17% of their Caucasian counterparts (Mummidi, et 
al. , 1998). 
Table: 2.1.1 : The frequencies of chemokine and chemokine receptor variants in different 
populations. 
Population Gene Variants and Allelic Frequency(%) 
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Most studies investigating host genes associated with resistance to infection have 
focused on Caucasian cohorts. Studies analysing the chemokine receptors and their 
ligands have shown that only mutations in the CCR5 gene confer resistance to infection. 
However, mutations affecting levels of expression of the receptors or their ligands have 
been shown to play a role in the rate of disease progression. As the role of these genetic 
variants may influence susceptibility to infection and therefore the dynamics of HIV-1 
transmission, it is useful to screen for these mutations in South African highly exposed 
but persistently seronegative (HEPS) population, where their role in HIV-1 transmission 
has never been investigated. In this study four of these genetic polymorphisms, namely 
CCR5t.32, CCR5m303, CCR2b-64I and SDF1-3'A were screened for in a population of 
17 HEPS sex workers to ascertain their frequency and role, if any, in HIV-1 resistance. 
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2.2) MATERIALS AND METHODS 
2.2.1 Study Population 
The study was done on samples from 17 African (black) HEPS commercial sex workers 
from KwaZulu/Natal who, despite multiple sexual exposures for over four years, have 
resisted HIV-1 infection. See Table 2.2.1 for the characteristics of the study population. 
Samples were obtained from G. Ramjee (MRC, S.A) from an established sex worker 
cohort (Ramjee, et al., 1998). 
This cohort includes women from five truck-stops in the KwaZulu/Natal midlands area of 
South Africa who were recruited to participate in a number of prevention programmes 
including literacy and condom usage programmes and a Phase III microbicide trial 
(Ramjee, et al., 2000). Informed consent was obtained from all participants and ethical 
approval was acquired from all participating institutions (Universities of Natal, 
Witswatersrand and Cape Town). 
Women participating m the microbicide trial were screened monthly for sexually 
transmitted infections (STis) including HIV-1. STis screened for include Trichomonas 
vagina/is, Neisseria gonorrheae, Chlamydia trachomatis, Haemophilus ducreyi and 
Treponema pallidunam. Antibody to HIV-1 was detected using HIV-1-s ELISA (Abbott, 
Chicago), and second confirmatory ELISA was performed using the Vironostika HIV-I 
Uniform II micro-ELISA 4 system (Omnimed, UK). For details of STI results from this 
cohort please refer to Ramjee et al., (1998). 
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Table 2.2.1 : Characteristics of the study population* 
Sample #Age Part-1ers Condom Anal sex CD4 CD4:CD8 **Years in 
ID ~er/wk use(%) count sex work 
Du4 39 10 50-75 Yes 939 2.139 4.10 
Du6 24 16 25-50 No 921 1.393 6.5 
Du7 24 15 <25 No 1523 1.765 13.5 
Du20 38 10 25-50 No 739 1.711 26.1 
Du53 27 21 25-50 Yes 1250 1.553 5.5 
Du85 30 10 25-50 Yes 1429 1.100 5.1 
Du96 25 27 50-75 Yes 960 2.172 6.5 
Du117 31 16 25-50 Yes 1172 3.417 7.5 
Du126 38 24 25-50 Yes 879 2.021 8.5 
Du154 18 9 25-50 No 1191 0.855 4.8 
Du175 38 20 25-50 No 875 1.519 7.10 
Du188 36 40 25-50 Yes 621 2.416 5.11 
Du205 27 10 25-50 No 739 1.334 8.0 
Du250 25 10 25-50 No 780 1.889 8.5 
Du270 38 11 25-50 Yes 773 2.438 9.1 
Du272 30 12 25-50 No 1113 2.553 14.1 
Du366 30 21 25-50 Yes 960 1.282 7.5 
*Information provided by Dr. G. Ramjee, (MRC-Durban) 
1Age at time of recruitment (Sep. 1996 - Oct.1997) 
**Years in sex work at time of sample collection (Nov. 1999) 
Table 2.2.2 depicts all the sexually transmitted infections (STis) tested for in the sex 
work cohort at the time of recruitment. 
Table 2.2.2 : Prevalence of sexuallr transmitted infections in the sex work cohort* 
Sample Condom Incidence of STis at screening 
ID use(%) Trichomonas Candida. .Neisseria. Haemophilus .Chlamydia Treponema 
vagj_nalis albicans ~onorrheae ducreyi trachomatis pallidunam 
Du4 50-75 Neg. Neg. Pos. Neg. Pos. Neg. 
Du6 25-50 Neg. Pos. Neg. Neg. Pos. Neg. 
Du7 <25 Neg. Pos. Pos. Neg. Neg. Neg. 
Du20 25-50 Neg. Neg. Neg. Neg. Neg. Pos. 
Du53 25-50 Neg. Pos. Neg. Neg. Neg. Pos. 
Du85 50-75 Pos. Neg. Neg. Neg. Neg. Neg. 
Du96 25-50 Neg. Pos. Neg. Neg. Neg. Neg. 
Dul17 25-50 Neg. Neg. Neg. Neg. Pos. Neg. 
Dul26 25-50 Neg. Neg. Neg. Neg. Neg. Pos. 
Du154 25-50 Pos. Pos. Neg. ND Pos. Pos. 
Du175 25-50 Neg. Neg. Neg. ND Neg. Neg. 
Du188 25-50 Neg. Neg. Neg. ND Neg. Neg. 
Du205 25-50 Pos. Pos. Neg. ND Neg. Pos. 
Du250 25-50 Neg. Neg. Neg. ND Neg. Neg .. 
Du270 25-50 Neg. Neg. Neg. ND Neg. Neg. 
Du272 25-50 ND ND ND ND ND ND 
Du366 25-50 Pos. Pos. ND ND ND Pos. 
*Informatiom provided by DR. G. Ramjee (MRC, S.A) Durban. 
Neg. = Negative 
Pos. = Positive 
ND=Notdone 
2t. 
2 .2.2 Detection of genetic polymorphisms in chemokines and chemokine 
receptors 
The chemokine receptor mutation (CCR51132) was detected by polymerase chain 
reaction (PCR) and CCR5m303, CCR2b-64I and SDFl-3 ' A polymorphisms were 
detected by PCR followed restriction fragment length polymorphism (RFLP). Genomic 
DNA was isolated from peripheral blood mononuclear cells (PBMC) of 17 HEPS 
individuals using the Pure PCR Template Preparation Kit (Boerhinger Mannheim, 
Germany) according to the manufacturer's instructions. DNA was amplified using the 
Perkin Elmer 9600 thermocycler following the PCR cycling protocols shown in Table 
2.2.4. 
Table 2.2.4 : PCR protocols and MgClz concentration for different chemokine receptor genes 






95°C, 60°C and 72°C for 30s at each temperature 
94°C, 58°C and 72°C for 20s at each temperature 
94°C, 63°C and 72°C for 20s at each temperature 
94°C, 65°C and 72°C for 30s at each temperature 
The following were used for the PCR master mixes ; standard PCR buffer (1 OmM Tris-
HCL, pH 8.3; 50mM KCL), lOmM of deoxynucleotide triphosphates (dNTP), 
25pmol/µl of each primer, 0.125µ1 (5U/µl) Super Therm (Taq) polymerase (ICN, 
Biochemicals, USA) in a total volume of 20µ1. 
a) CCR5~32 Detection 
The CCR5 primers, CCR5 (F) and CCR5 (R) (Table 2.2.5) amplified a 225bp fragment of 
the CCR5 gene including the CCR5L'.i32 mutation site. The CCR5 wild type allele 
generated a 225bp fragment and the mutant allele (CCR5L'.i32) generated a 193bp DNA 
fragment, 32bp shorter than the fragment generated by the wild type allele. All PCR master 
mixes were made up to 20µ1, each containing 2.5µ1 of the lOX buffer, 2µ1 of lOmM 
dNTPs, 1.0µ1 of each primer (25pMol/µl) , 5.0µ1 of DNA template, MgCh and made up to 
20µ1 with distilled water. DNA amplification cycling and the concentration of MgCh used 
in each PCR programme are shown in Table 2.2.4. The PCR products were visualized on 
2.5% agarose gel containing ethidium bromide (1 Ong/ml) after gel electrophoresis. 
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Table 2.2.5 : PCR primers for detection of chemokine and chemokine receptor polymorphisms 
Name Gene Sequence References 
variant 
CCR5 (F) CCR56.32 5'-TAATACGACTCACTATAGGG-'3 Michael, et al. , (1997) A 
CCR5 (R) CCR56.32 5 ' -GTTTTCCCAGTCACGACG-'3 Michael, et al., (1997) A 
CCR5-m303 (F) CCR5m303 5'-GCTGCAGGTGTAATGAAGAC-'3 Williamson, et al., 2000 
CCR5-m303 (R) CCR5m303 5'-CTGAAGAGCATGACTGACAT-'3 Williamson, et al., 2000 
CCR2b (F) CCR2b-641 5 '-TTGTGGGCAACA TGA TGG- '3 Michael, et al., ( 1997) B 
CCR2b (R) CCR2b-64I 5 ' -TGTGAA T AA TTTGCACA TTG- '3 Michael, et al., (1997) B 
SDF-1 (F) SDFl-3 'A 5 '-CAGTCAACCTGGGCAAAGC-'3 Winkler, et al. , ( 1998) 
SDF-1 {R} SDF1-3'A 5 '-AAGCTTTGGTCCTGAGAGTC- '3 Winkler, et al., { 1998} 
b) CCR5m303 Detection 
For the detection of the CCR5-m303 polymorphism, the primers used CCR5m303 (F) 
and CCR5m303 (R) (Table 2.2.5) amplified a 350bp fragment of the CCR5 gene that 
included the CCR5m303 polymorphic site. 
DNA amplification cycling was carried out as shown in Table 2.2.4. Amplified DNA 
fragments were analysed by restriction fragment length polymorphism (RFLP) using the 
restriction endonuclease, Hine II (Boerhinger Mannheim, Germany). All the restriction 
digests were carried out as described by Sambrook, et al., (1989). A single digestion 
reaction (5µ1) contained 2.5µ1 of buffer, 0.5µ1 of Hine II (500U/ml) and 2µ1 of distilled 
water, was added to the 20µ1 PCR product and incubated for 4 hours at 37°C. 
The CCR5m303 wild type allele has a restriction site for Hine II and the mutant allele 
loses this restriction site. Two fragments of 230 and 120bp were generated for the 
CCR5 wild type allele, and a 350bp fragment was generated for the homozygote mutant 
allele. The PCR products analysed by gel electrophoresis and were visualized on 2.5% 
agarose gel containing ethidium bromide ( 1 Ong/ml). 
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c) CCR2b-64I Detection 
The primers CCR2 (F) and CCR2 (R) (Table 2.2.5) were used for the detection of 
CCR2b-64I polymorphism. DNA amplification cycling was carried out as shown in 
Table 2.2.4. The PCR product generated a l 83bp fragment that included the site of a 
single nucleotide substitution in the CCR2 gene (Smith, et al., 1997). Amplified DNA 
fragments were analysed by restriction fragment length polymorphism (RFLP) using 
BsaB I (ICN Biomedicals, USA) endonuclease. 
A 5µ1 restriction digest mix containing 2.5µ1 of buffer, 0.5µ1 of BsaB I (l,OOOU/ml) 
and 2.0µ1 of distilled water, was added to the 20µ1 PCR product and incubated for an 
hour at 60°C. The CCR2b-64I allele has a restriction site for BsaB I and the wild type 
allele (CCR2b) loses its restriction site. Two fragments of 165 and 18bp were generated 
for the CCR2b-641 homozygous allele. The wild type allele generated a fragment of 
183bp. 
d) SDF1-3'A Detection 
Primers SDF-l(F) and SDF- l(R) (Table 2.2.5) were used to amplify a 303bp DNA 
fragment of the SDF-1 gene, including the SDF1-3'A polymorphic site (Winkler, et 
al., 1998). DNA amplification cycling was carried out as shown in Table 2.2.4. 
Amplified DNA fragments were analysed by restricticn fragment length 
polymorphism (RFLP) using Msp I (Boerhinger Mannheim, Germany) 
endonuclease. A 5µ1 restriction digest mix containing 2.5µ1 of buffer, 0.5µ1 of 
Msp I (1,000U/ml) and 2µ1 of distilled water, was added to the 20µ1 PCR product 
and incubated for 4 hours at 3 7°C. The SDF-1 wild type allele has a restriction site 
for Msp I and the mutant (SDF 1-3 'A) allele loses its restriction site. Two fragments 
of 179 and 124bp were generated for the SDF-1 wild type allele, and a 303bp 
fragment was generated for the homozygote mutant allele. 
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2.2.3 Sequencing 
A 'l()'lbn D1'.T A ~ .. gm0nt of the SDF l gono f-h"t ;nc111 AeA f-ho ~Dt.l 'l' A pol,1 ....... orphi"' ii.. JV.J J-' .L."'lii. .1..1U. J.J.U.11. -1. \,,,U.'-' L J.U. ll J.UU U LI.I.'-' t,J ..I. 1.-.J ii.. jl.U. V 
Sl.te rnr;nt-Jer nf al I 092) "'as c,0,.,11.onr>eA So,.,uon,..;no U7'>C' no...C.ormoA hu 11...fr Doi-or \ t", J...l.il......_ .1., '-'• ... , .I../ V YY "''-''fU'-'..l.1.'-' U. '-''f "'J.\,.I.UJ.E, Y\'U,..:, t''-'11~ .l .1..1."'U. UJ .1.\'.A....l .I.. '-'L'-'.l 
Owira of the Depa.rtment of Medical Microbiology Universit'J of Cape Town using the 
ABI Prism 310 Genetic Analyzer (Perkin Elmer). The forward and the reverse stra.'lds 
were aligned and compared to a published sequence, polymorphisms were identified by 
a.'lalysis of aligned sequences using the Auto Assembler 2.1 package of the Prism 310 
Genetic 1\nalyzer. 
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2.3 ) RES UL TS 
Seventeen women were identified who had been in sex work for greater than four years, 
while remaining HIV-1 negative. Four years was selected based on data generated from 
the sex-worker cohort in Nairobi which showed that women were most likely to 
become infected in the first two years of sex work and the risk of infection decreases 
with every year in sex-work thereafter (Fowke, et al., 1996). 
A similar analysis is not yet available on the KwaZulu/Natal cohort, and the inclusion 
of these women into the HEPS cohort will have to be reviewed once the analysis is 
complete. 
In general, these women had proven exposure to HIV-1 as they had a low reported 
frequency of condom usage, which was reflected in the high prevalence of sexually 
transmitted infections (STis) detected at entry to the study (Table 2.2.2). In addition, the 
overall HIV-1 incidence in this cohort is 18% (G. Ramjee p~rsonal communication). 
The time in sex work ranged from four years eight months to 26 years with an average 
of nine years. The average number of partners per week was 17 with the reported 
condom usage in 16 of the 17 women being below 50%. The prevalence of HIV-1 
among the truck drivers who are clients to these sex workers is reported to be 56% (G. 
Ramjee personal communication). 
Women were screened for mutations or genetic polymorphisms in three chemokine 
genes namely, CCR5~32, CCR5m303 and CCR2b-64I, and the untranslated terminal 
repeat (UTR) of one chemokine ligand, SD F 1-3 'A. The frequencies of these variants in 
the HEPS were compared to previously published frequencies from South African 
populations. 
The CCR5~32 mutation is characterised by a 32bp deletion. The CCR5 wild type allele 
produces a 225bp DNA fragment and the mutant allele produces a fragment of 193bp. 
The CCR5m303 va~iant is characterised by an elimination of a Hine II restriction site. 
The wild type allele produces two DNA fragments of 230 and 120bp, the mutant allele 
produces a 350bp fragment. CCR2b-64I variant has a BsaB I restriction site that is lost 
by the wild type CCR2b allele. The wild type allele produces a 183bp fragment and the 
mutant allele produces two fragments 165 and l 8bp long. 
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The SDF-1 ligand has a Msp I restriction site which is lost by the mutant allele (SDFl-
3 'A). The wild type allele produces a fragment of 179 and 124bp and the mutant allele 
produces a fragment of 303bp. In Table 2.3.1 band sizes characteristic for each chemokine 
and chemokine receptor variants are presented. 
Table 2.3.1: Sizes of bands characteristic for different genotypes 





Wild type Heterozygous 
(wt/wt) (wt/vt) 
225bp 225 and l 93bp 
183bp 183, 165 and 18bp* 
179 and 124bp 303, 179 and 124bp 
230 and 120bp 350, 230 and 120bp 
*Band not visible in regular agarose gel. 
wt/wt= wild type 
wt/vt = heterozygote (wild type/variant) 




165 and l 8bp* 
303bp 
350bp 
Among the 17 HEPS individuals tested for the CCR5m303 and CCR5~32 mutations by 
RFLP and PCR respectively, no mutant alleles were detected (Table 2.3.3). These two 
mutations have previously been shown to be rare among the African population 
(Williamson, et al., 2000). The typical gel electrophoresis results of CCR5~32 and 
CCR5m303 genotyping are presented in figure 2.3.1 a and b. 
A. 
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Figure 2.3.1 : Detection of chemokine (SDF-1) and chemokine receptor (CCR2b and CCR5) variants in a 
population of HEPS by PCR and PCR-RFLP analysis. (a) CCR5~32 mutation detection, all samples (lanes 
1-17) were CCR5 wild type (w/w) band size 225bp. Lane 18 positive control known heterozygote (w/~32) 
band sizes 225 and 193bp. (b) Detection of the CCR5m303 variant, all samples (lanes 1-17) were wild type 
band sizes 230 and 120bp. (c) Detection of CCR2b-64I variant, CCR2b-64I heterozygous (w/64I) lanes (2, 
11 and 15) band sizes 165, 14 7 and I 8bp (not visible). CCR2b wild type (w/w) lanes 
(1,3,4,5,6,7,8,9,I0,12,13,14, and 16) band size 165bp. CCR2b-64I homozygotes (64I/64I) lane (17) band 
sizes 147 and 18bp (not visible) . (d) SDFl-3'A detection, SDF-1 wild type (w/w) lanes 
(l,2,3,5,6,7,8,9,10,11,12,15,16,17) band sizes 179 and 124bp. SDFl-3'A heterozygotes (w~3'A) lanes (4,13 
and 14) band sizes 303, 179 and l 24bp. All bands visualised on 2.5% agarose gel containing Ethidium 
bromide ( I Ong/ml). 
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Seventeen HEPS individuals were genotyped for CCR2b-64I polymorphism by PCR-
RFLP (Figure 2.3. lc). Among the HEPS population an allelic frequency of 15% (Table 
2.3 .3) was determined. This compared with a frequency of 13 % in the South African 
population (Williamson, et al., 2000). 
Highly exposed but persistently seronegative (HEPS) women were genotyped for 
SDFl-3' A variant by PCR-RFLP. Among the HEPS population three individuals were 
identified as being heterozygous for this variant. A typical gel electrophoresis result of 
the SDF-1 genotyping is presented in figure 2.3. ld. However, only two out of three of 
these variants were confirmed by sequencing, indicating that the enzyme was not 
digesting to completion. Figure 2.3.2 depicts the polymorphisms in the HEPS samples 
as compared to a wild type sequence. Sequence analysis did not reveal any other 
variant in this region. The confirmed allelic frequency of this variant was therefore 
5.9%. This compared with a frequency of only 1% in the South African population 
(Williamson, et al., 2000), and the difference between HEPS and the background 
frequency in the South African population was markedly significant. 
A 
B. 
AGACC C GGCT 
l 
It ~ .. 
TIC 
Fig. 2.3.2 : SDF-1 sequence chromatographs showing the difference between the SDF-1 wild type, 
(A) and heterozygote (B) variants. 
In summary, the allelic frequencies of the CCR5L\32, CCR5m303 and CCR2b-64I 
variants were comparable between the HEPS and the general South African 
population, whereas the HEPS had an elevated frequency of the SDFl-3 'A variant 
compared to the South African population. 
Table 2.3.3 : Genotype and allelic frequencies found in the study population versus 
allelic frequencies found in the South African population (SAP)* 
Gene Variant Genotype Allelic Frequency 





(wt/wt) (wt/vt) (vt/vt) 
HEPS SAP* HEPS SAP* HEPS SAP* 
17 1245 0 2 0 0 
17 687 0 0 0 0 
12 134 3 44 1 2 
14 194 3 4 0 0 
*Williamson, et al. , (2000). Study dont on South African Population. 
wt/wt = wild type 
wt/vt = heterozygote (wild type/variant) 















2.4 ) DISCUSSION 
Global, regional and ethnic distribution of frequencies of IBV/AIDS protective 
mutations can vary significantly (Table 2.4.1). The CCR5~32 mutation is extremely 
rare among Africans (Huang, et al., 1996) and its frequency is different even among 
the Caucasian population with higher frequencies in Europeans from Northern Europe 
(20%) compared to those in Southern Europe (2.0%) (Martison, et al., 2000). CCR2b-
64I variant exist at a higher frequency (13.3%) in the African and the African 
American (27.7%) populations than in Caucasians (17.7 -27.7%) (Williamson, et al., 
2000 and Mummidi, et al., 1998). The SDFl-3 'A variant is more frequent in 
Caucasians (39%), compared to African Americans (15 .1%) (Huang, et al., 1996 and 
Mummidi, et al., 1998). In South Africa Caucasians have a frequency of 20.3% 
compared to only 1% in Africans (Williamson, et al., 2000). 
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Mutations that result in non-functional CCR5, such as CCR5~32 and CCR5-m303, 
confer resistance to IBV-1 infection (O'Brien, et al.,1997 and Quillent, et al., 1998), 
however, these mutations were not responsible for resistance in the women 
participating in this study. This is not surprising as these mutations are extremely rare 
in individuals of African origin. 
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In a recent study by Petersen, et al., (2001) several novel mutation in the CCR5 gene 
were found which had no effect on HIV-1 resistance, included in that study were seven 
HEPS women from this cohort. 
One out of the 17 HEPS samples genotyped for CCR2b-64I was homozygous (64V64I) 
and three of the 17 samples were heterozygous (wt/641), giving the allelic frequency of 
15% for this study population. This value compares well with the allelic frequency of 
13.1 % reported for South African population (Williamson, et al., 2000). This mutation 
is not associated with protection from HIV-1 infection but was found to delay disease 
progression in HIV-1 infected individuals (Smith et al., 1997). 
The role of the SDF1-3'A variant is controversial. The SDF1-3 'A variant has been 
reported to both delay the rate of progression to AIDS in individuals who are 
homozygous (SDF 1-3 'A/3 'A) for this variant (Winkler, et al. , 1998), while other 
researchers have found homozygosity results in more rapid progression after diagnosis 
of AIDS (Brambila, et al ., 2000). Interestingly, Winkler et al., ( 1998) found that 
heterozygosity had a protective effect against HIV-1 infection. In the study by Winkler 
et al., ( 1998) a group of high-risk exposed uninfected individuals showed a highly 
significant elevation in SDF1-3'A variant wherein more than half (50.6%) were 
heterozygous (wt/3 'A) for the SDF-1 allele compared to 31. l % among infected 
individuals. In the current study HEPS women were found to have an allelic frequency 
of 5.8% (two out of 17 were heterozygote) compared with only 1 % in the background 
population (4 out of 198) individuals were heterozygous (Williamson, et al., 2000). 
In conclusion, none of the well characterised mutations in the CCR5 gene associated 
with resistance were identified in this study population. However, an elevated 
frequency of the SDF 1-3 'A variant was observed. The mechanism of how this variant 
confer resistance is puzzling as sexually transmitted HIV- I strains generally utilize the 
CCR5 receptor and not CXCR4. Further work needs to be done to ascertain the role of 
this variant in Hiv-·1 pathogenesis. 
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3.1) INTRODUCTION 
Some individuals remain uninfected by HIV-1, despite multiple sexual exposures to the 
virus. Peripheral blood mononuclear cells (PBMC) of such individuals are resistant to in 
vitro infection by RS viral strains, but not X4 viral strains (Connor, et al., 1997 and 
Paxton, et al., 1996). This resistance is associated with a homozygous 32bp deletion 
(~32) in the CCR5 gene (Samson, et al., 1996 and Liu, et al., 1996) that renders the 
receptor non-functional. Resistance of PBMC to R5 HIV-1 viral strains was found to be a 
result of a blockage at the level of viral entry (Dragic, et al., 1996). Individuals 
heterozygous for the CCR5 deletion (CCR5~32) are susceptible to infection (Dean, et al., 
1997) and their PBMC are permissive for CCR5 dependent HIV-1 strains (Samson, et al., 
1996). However, these individuals have delayed disease progression possibly as a 
consequence oflow levels of CCR5 expression (Husman, et al., 1999). 
The role of B-chemokines, natural ligands for CCR5, in the pathogenesis of HIV-1 has 
been studied extensively in vivo and in vitro. Several studies have shown that B-
chemokines can inhibit replication of R5 viruses in vitro (Alkhatib, et al., 1996 and 
Dragic, et al., 1996). Paxton, et al (1996) reported that highly exposed but uninfected 
individuals produced high amounts of B-chemokines RANTES, MIP-la and MIP-lB 
(Paxton, et al., 1996) which may contribute to their natural resistance to HIV-1 infection. 
Primary HIV-1 isolates in early disease stage use CCR5 as a coreceptor, these viruses are 
classified as R5 or non syncytium-inducing (NSI) based on the cytopathic effect they 
have on the MT-2 cell line. In HIV-1 subtype-B, as disease progresses there is an 
emergence of syncytium-inducing (SI) viruses which utilise the CXCR4 receptor (R5X4 
or X4 viruses). The emergence of these variants results in a decline in CD4 T-cells and 
rapid disease progression (Samson, et al., 1996). 
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The expression levels of CCR5 are crucial in the in vitro cell infectability by HIV-1 R5 
isolates (Reynes, et al., 2000). The two chemokine receptors (CCR5 and CXCR4) are 
differentially expressed in different CD4 T-cell subpopulations. CCR5 is mainly 
expressed in memory and activated T-cells and CXCR4 is expressed in naive T-cells 
(Bleul, et al., 1997). HIV-1 infected individuals heterozygous for the b.32 deletion have 
some advantage over CCR5 homozygote wild-type individuals in relation to disease 
progression (Zimmerman, et al., 1997). The mechanism by which heterozygous 
individuals are protected against disease progression is not fully understood. It has been 
demonstrated that in vitro infectability correlates with CCR5 expression levels at the cell 
surface, which in tum is influenced by the genotype of the CCR5 gene (Wu, et al., 1997). 
Ostrowski, et al., (1998) demonstrated that CXCR4 on CD4 T-cells is significantly down 
regulated, and CCR5 expression is up-regulated in HIV-1 infected individuals compared 
with uninfected controls (Ostrowski, et al., 1998). 
In addition, differential functioning of these receptors may be a factor in HIV-1 
resistance. Individuals who are infected with HIV-1 and carrying the wild type CCR5 
allele were found to have higher levels (28%) of CD4 T-cells expressing CCR5 compared 
to HIV-1 infected individuals who are heterozygous (21%) for the CCR5b.32 mutation 
(Husman et al., 1999). Lower expression levels of the CCR5 receptor correlates to 
reduced infectability of CD4 T-cells with R5 HIV-1 isolates in vitro (Wu, et al., 1997). 
HIV-1 infected individuals who progress rapidly to AIDS have higher levels of CD4 T-
cells expressing CCR5 than slow progressors (Husman, et al., 1999). There is a 
significant correlation between disease stage and chemokine receptor expression levels, 
with CXCR4 expression levels higher than the CCR5 levels in the early stages of the 
disease. In advanced disease stage the expression levels of CCR5 are higher than the 
expression levels of CXCR4 (Ostrowski, et al., 1998). 
To determine the influence of chemokine receptors in HIV-1 pathogenesis in HEPS 
individuals, the levels of CCR5 and CXCR4 were quantified on unstimulated PBMC 
from 17 HEPS and a control group of five HIV-1 seronegative women. 
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In addition, we examined whether resistance to HIV-1 infection in HEPS is associated 
with differences in the susceptibility of their CD4 T-cells to infection with phenotypically 
distinct primary isolates ofHIV-1 including RS, R5X4 and X4 of different subtypes. 
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3.2) MATERIALS AND METHODS 
a) Blood samples 
Blood samples were obtained from 17 sex workers who had previously tested HIV-1 
antibody negative despite repeated exposure to HIV-1 (HEPS). These samples were re-
tested for antibodies to HIV using an ELISA assay (Genscreen HIV-1/2 version 2, Sanofi 
Pasteur, France) and for CD4 T-cell numbers by flow cytometry (Becton Dicknson) at the 
National Institute for Virology. A group of five HIV-1 seronegative laboratory co-
workers considered to be at low risk of HIV-1 infection were used as controls. 
b) Isolation of PBMC 
PBMC were isolated from approximately 20ml of whole blood by Ficoll hypaque density 
gradient centrifugation. Whole blood was centrifuged at 1,500rpm for 15 minutes and the 
plasma collected and stored. The buffy coat was removed and mixed with 5ml of 
phosphate buffered saline (PBS). This cell suspension was carefully layered onto 5ml 
Ficoll (Pharmacia) in a 15ml conical tube and centrifuged at 2,000 rpm for 30 minutes at 
room temperature with brake off. 
The mononuclear cells which sedimented on top of the Ficoll layer were carefully 
removed and washed twice in PBS at 1,000 rpm to remove platelets. Viable cells were 
counted using trypan blue exclusion criteria under a hemocytometer. 
c) Quantification of chemokine receptor expression levels by flow cytometry. 
The proportion CD4 T-cells positive for CCR5 and CXCR4 was measured on 
unstimulated CD4 T-cells from HEPS and controls by three colour flow cytometry. This 
part of the work was done under the guidance of Ms Stephina Nyoka at the National 
Institute for Virology. 
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PBMC (2 x 105) were labelled with anti-human CD3-APC (SK7) and anti-human CD4-
PerCP (Becton Dickinson) to delineate CD4 positive T-cells. To this was added either 
anti-human CCR5-FITC (2D7), or anti-human CXCR4-PE (12G5) (BD Pharmingen). All 
antibodies were diluted 1: 10 in PBS in a total volume of 50µ1. IGg2a-FITC and IGg2a-
PE (Becton Dickinson) were used as isotype controls. Cells were then washed with PBS 
containing 0.5% bovine serum albumin (BSA) and fixed in 200µ1 of PBS containing 2% 
BSA and 5% formalin for 10 minutes. Acquisition and surface staining analysis was 
performed using Cell Quest software program 3.2.1 (BD Facsort, San Jose, CA). 
Statistical analysis was done using the Mann Whitney student t-test performed on Prism 
2.0 program. 
d) Cell culture 
Isolated PBMC were stimulated with 5µg/ml phytohemagglutinin (PHA) (Sigma, USA) 
for 72 hours in RPMI 1640 medium supplemented with 20% fetal calf serum plus 100 
U/ml of streptomycin and penicillin ( complete medium) at a density of 2 x 106/ml in a 15 
ml flask at 37°C. After two-three days cells were washed and counted and used as targets 
for HIV-1 infection assays. 
e) HIV-1 isolates used in the study 
PBMC from both HEPS and controls, were exposed to three R5 (Du151, Du422, and 
SM2), one X4 (Acute6) and two R5X4 (Dul 79 and CM9) HIV-1 tropic viral strains 
(Table 3.1). Four of the HIV-1 viral strains were HIV-1 subtype-C (Du151, Du422, 
Du179 and CM9), one was HIV-1 subtype-B (SM2) and one was an HIV-1 subtype-D 
(Acute 6). The three isolates with the Du prefix were collected from women in the same 
geographic region as the women in the HEPS cohort. Three of the isolates caused syncitia 
(SI) in the MT-2 cell line and this correlated with their ability to use the CXCR4 
coreceptor. Two of these isolates also used CCR5 and were classified as dual-tropic. 
Three isolates were non-syncitium inducing (NSI) and used the CCR5 coreceptor only. 
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The MT-2 and coreceptor assays were performed by Mr Tonie Cilliers at the National 
Institute for Virology. 
Table 3.1: Genotypic and phenotypic characteristics of HIV-I isolates used in the study 
Isolate Subtype gaglenv MT-2 assay Co-receptor used 
Du 151 CIC NSI CCR5 
Du422 CIC NSI CCR5 
Du 179 CIC SI CCR5ICXCR4 
CM9 CIC SI CCR5ICXCR4 
SM2 -/B NSI CCR5 
Acute 6 DI- SI CXCR4 
t) In vitro infectivity assay 
Mitogen-stimulated PBMC from HEPS and control subjects were plated at a density of 2 
x 105 cells per well in 96-well plates, in complete RPMI medium containing IL-2 (5%) in 
a volume of 100µ1. Cultures were inoculated with approximately 1,000 TCID50 of various 
HIV-1 isolates in a final volume of 200µ1. Virus replication was assessed at regular 
intervals (days 4, 7, 10, and 14) over a two week period by measuring the production 
HIV-1 p24 antigen in the culture supernatants by an ELISA assay. Half of the supernatant 
from the cultures was removed for the p24 assay, and replaced with fresh media 
containing IL-2. 
g) p24 antigen ELISA assay 
The levels of p24 antigen that accumulated in tissue culture supernatants were measured 
using an in-house p24 antigen ELISA (Appendix B4). For this, each well of a high 
binding 96 well plate was coated with 100µ1 of anti-HIV-1 p24 antibody (D7320, Aalto 
Bio, Ireland) and incubated overnight at room temperature. Plates were washed twice 
with Tris Buffered Saline (TBS) followed by 100µ1 of 2% milk in TBS (to block non-
specific binding sites on the plate) and incubated for 1 hour at room temperature. 
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Plates were washed once with TBS after which 100µ1 of culture supernatant plus 100µ1 of 
1 % Empigen ( to inactivate the virus) was added to each well. Plates were incubated for 2 
hours at 37 C, after which they were washed thoroughly with TBS. 
To each well 100µ1 of anti-HIV1-p24 antibody conjugated to alkaline phosphatase 
(EH12AP, Aalto Bio, Ireland) in 2% sheep serum (Sigma) and 0.05% Tween in TBS was 
added and incubated for 1 hour at 37 C. Plates were washed 4x with AMPAK buffer 
(Dako) using an automated washer, followed by the addition of 50µ1 AMP AK substrate 
(Dako) and incubated for an hour at room temperature. After this 50µ1 of AMP AK 
amplifier (Dako) was added for 3 minutes at room temperature and then 50µ1 of stop 
solution (0.5 M HCL) was added. The optical density (OD) was read using an automatic 
plate reader at 492nm. Positive and negative controls were included in all ELISA'S. 
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3.3) RES UL TS 
All the samples from the HEPS women used in this study were confirmed as HIV-1 
seronegative by ELISA. The CD4 T-cell count of all the samples was within the normal 
range of 500-1,200cell/µl indicating that these women had no evidence of 
immunosuppession (Table 3.3.1). 
Table 3.3.1: Depicting the HIV-1 status of the HEPS women 
Sample ID IDV-1/2 antibody CD4 T-cell count ( cells/µl) 
Du4 Negative 939 
Du6 Negative 921 
Du7 Negative 1523 
Du20 Negative 739 
Du53 Negative 1250 
Du85 Negative 1429 
Du96 Negative 773 
Dul 17 Negative 1172 
Dul26 Negative 879 
Dul54 Negative 1191 
Dul75 Negative 875 
Du188 Negative 621 
Du205 Negative 739 
Du250 Negative 780 
Du270 Negative 759 
Du272 Negative 1113 
Du366 Negative 960 
Average 980 
a) Chemokine receptor expression levels 
The percentage of CD4 T-cells positive for CCR5 and CXCR4 of 17 HEPS and four 
controls was determined by three-color flow cytometry. The mean percentage of CD4 T-
cells positive for CCR5 was 10.7% (STD deviation 10.6%) for HEPS and 1.7% (STD 
deviation 6.8%) for the control group (Table 3.3.2). The difference in CCR5 levels 
between the two groups was not statistically significant (p=0.117). Similarly, the 
difference in CXCR4 positive CD4 T-cells in the HEPS and the control group was not 
statistically significant (p=0.964). The mean percentage of CD4 T-cells positive for 
CXCR4· for HEPS was 89.3% (STD deviation 9.4%) and for the control group 88.3% 
42 
(STD deviation 3.0%) (Table 3.3.2). The proportion of CD4 T-cells expressing CXCR4 
was higher than for CCR5 in both groups. 
In order to determine whether the levels of CCR5 and CXCR4 receptor expression on 
CD4 T-cells differed between HEPS and controls we analyzed the mean fluorescence 
intensity (MFI) (Table 3.3.2). For CCR5 the MFI on HEPS and controls was 16.2 and 
11.1 respectively. For CXCR4 it was 151.7 (HEPS) and 138 (controls). The difference in 
expression levels of both chemokine receptors was not statistically significant for CCR5 
(p=0.433) or CXCR4 (p=2.13) between the two groups. 
Collectively these data indicate that both HEPS women and controls had similar 
proportions on CD4 T-cells positive for CCR5 and CXCR4, and that the levels of 
expression of both chemokine receptors was similar in both groups. 
Table 3.3.2 : CCR5 and CXCR4 expression levels on CD4 I-cells of HEPS women and controls 
SamElelD Mean fluorescence intensi!X (MF!} % Eositive CD4 T-cells 
CCR5 CXCR4 CCRS CXCR4 
Du4 9.6 126.9 1.0 97.6 
Du6 14.3 47.4 24.8 78.1 
Du7 17.7 272.2 0.5 98.2 
Du20 40.6 153.8 37.3 95 .9 
Du53 10.0 58.2 15.0 79.1 
Du85 19.2 114.8 11.8 93.1 
Du96 10.5 236.5 2.0 98.9 
Dul 17 9.8 234.2 2.3 99.5 
Dul26 9.7 147.7 1.3 98.0 
Dul54 11.6 49.5 19.9 67.4 
Dul75 10.1 150.9 23 .8 77.0 
Dul88 48.9 335.7 7.6 84.8 
Du205 11.9 187.6 3.6 98.2 
Du250 16.5 158.7 7.0 83.1 
Du270 8.9 61.2 2.3 92.5 
Du272 8.7 160.2 1.0 92.5 
Du366 16.0 84.3 9.7 92.1 
Mean 16.2 151.7 10.7 89.3 
Control I 9.7 161 .2 1.4 95.2 
Control 2 11.0 139.0 2.7 87.1 
Control 3 9.2 173.7 1.0 93 .8 
Control 4 11.5 115.0 1.2 88.3 
Control5 13.8 101.4 2.3 77.3 

















There was considerable variability between individuals within the HEPS group in the 
expression of CCR5 on CD4 T-cells as observed by others (Moore, et al., 1997). This is 
shown graphically in Figure 3 .3 .1. A few HEPS women had higher levels of CCR5 than 
controls despite the fact that as a group there was no significant difference between them. 
Representative scatter plots of flow cytometric analysis of PBMC from three HEPS and 
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Fig 3.3.1 : CCR5 and CXCR4 expression levels on CD4 positive I-cells, of HEPS and HIV-I 
seronegative control individuals. 
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Fig. 3.3.3 : Representative scatter plots of flow cytometric analysis of CD4 T-cells from (A) Controls (l, 2 and 3) 
and (B) HEPS (Du96, Dul 79 and Du188). A three-color staining protocol was used to asses the expression of CCR5 
(x-axis) and CXCR4 (y-axis in all plots). Quadrants were set according to the staining of control mABs (IgG2a-FITC 
and IgG2a-PE). The percentage of stained cells is shown in each quadrant 
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b) PBMC in vitro infectivity assays 
PBMC from seven HEPS women and two controls were infected with HN-1 and 
monitored at regular intervals for HIV-1 p24 antigen production. The isolates used 
included three R5, two R5/X4 and one X4 isolate (Table 3.1). All viral isolates showed 
evidence of replication in cells from both HEPS and controls, except CM9 which 
replicated in only three of the seven HEPS samples (Table 3.3.2). The levels of 
replication of each viral isolate varied between PBMC samples as did the ability of each 
PBMC sample to support the replication of different viral isolates (Table 3.3.2). 
Table 3.3.2: Replication ofR5 and X4 tropic viral strains in PBMC from HEPS and control group. 
Du151 Du422 
Sample ID 
Du4 ++++ ++++ 
Du7 ++ + 
Du85 +++ + 
Dul 17 +++ +++ 
Du1 26 ++++ ++++ 
Du250 + + 
Du272 +++ +++ 
Control 1 +++ ++ 
Control 2 ++++ ++ 
< 250 p/ml = negative 
+ = 0.5 - I ng/ml 
++ = I - 2 ng/ml 
+++ = 2 - 4 ng/ml 
++++ = 4 - 8 ng/ml 



























The replication kinetics of all six isolates in two HEPS and one control PBMC sample is 
shown in Figure 3.3.3. Dul 79, an (R5/X4) virus showed the fastest replication kinetics 
with maximum p24 antigen levels by day four in both HEPS and control PBMC. This 
was clearly not the result of its ability to use both HIV-1 coreceptors as the other dual-
tropic virus, CM9 had the lowest replication capacity of all the viruses tested. In this case, 
p24 antigen was only observed after 11 days of infection in Du272 PBMC although the 
kinetics were slightly faster on control PBMC (Fig. 3.3.3). 
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Acute 6, the only X4 viral strain used established infection in all HEPS PBMC, but 
replicated poorly as indicated by the low HIV-1 p24 antigen production in Du7 and 
Du272 (Fig. 3.3.3). In both cases Acute 6, failed to reach maximum infection levels even 
after 18 days of infection. 
The three R5 isolates tested (Du151 , SM2, and Du422) infected all HEPS PBMC, 
although the replication of Du422 was slightly delayed compared with that of SM2 (Fig. 
3 .3 .3 ). Du 151 established the fastest infection with highest p24 antigen production among 
the three RS HIV-1 isolates. There were no apparent differences in the capacity to infect 
PBMC from HEPS and the control group by the three RS viral strains tested. 
Du7 PBMC supported viral replication of all viral isolates tested, except CM9 (Figure 
3.3.3). In these cells Du179 replicated to the highest level followed by Du151 and SM2 
while, Du422 and Acute 6 showed lower replication kinetics. A similar pattern was 
observed for Du272 PBMC although in this case CM9 did establish an infection in these 
cells, although replication rates were low. PBMC from the control sample supported 
replication of all viral isolates tested with Dul 79 and Du151 producing maximum p24 
antigen, followed by and CM9, with Acute 6 producing minimal p24 antigen. 
In summary, PBMC from HEPS women and the control sample showed no significant 
difference in their ability to support viral replication. For viral strains that failed to 
replicate (CM9) or those that replicated poorly (SM2 and Acute 6), it is clear that the 
failure of these isolates to replicate is a phenomena of the isolates themselves and not 
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Fig 3.3.3 : Kinetics of p24 antig~ production from PBMC inoculated with various strains of HIV-I 
on A) HEPS Du272, B) HEPS Du7 and C) Control sample. 
3.4) DISCUSSION 
PBMC from all the HEPS sex workers and the control group were infected by most of the 
HIV-1 viral strains used. The capacity to infect PBMC was shown not to be tropism 
specific, in that R5, X4 and R5/X4 viral phenotypes could initiate a productive infection. 
The above results also demonstrate that sufficient HIV-1 coreceptors are expressed on the 
cell surface of HEPS PBMC to facilitate infection. The mechanism underlying resistance 
to HIV -1 infection in these women is by some means other than cells being resistant to 
viral entry. 
Previous studies (Paxton, et al., 1996 and Connor, et al., 1996) have demonstrated that 
PBMC from HEPS individuals were resistant to infection by R5 viral strains due to a 
defective CCR5 protein (Paxton, et al., 1996). In this study we showed that blood cells 
from HIV-1 seronegative sex workers from KwaZulu/Natal could be infected with R5, 
R5X4 and X4 viral strains indicating that both the CCR5 and CXCR4 coreceptors were 
functional. This supports studies reported in Chapter 2 showing that all HEPS women had 
the wild-type CCR5 gene with no evidence for the delta 32 mutation. 
The levels of CCR5 expression have also been shown to correlate with susceptibility to 
infection with R5 strains, in vivo (Husman, et al., 1999). In our study there was no 
difference in the expression levels of both CCR5 and CXCR4 between the HEPS and the 
control group. There was however, considerable individual variability in the expression 
levels of CCR5 on PBMC. The variability observed, could be attributed to 
polymorphisms on the promoter region of the CCR5 gene. The influence of the CCR5 
promoter polymorphisms in HIV-1 pathogenesis is investigated in Chapter 4. A similar 
high level of variability has been reported by other authors and could be due to cytokine 
production, such as IL-2, IFNy, and IL-10 which upregulate CCR5 on the cell surface 
(Loetscher, et al., 1996 and Bleul, et al., 1997). It was reported that CCR5 levels are 
higher in cells of HIV-1 infected and uninfected Africans compared to their Italian 
counterparts, possibly as a result of a higher level of immune activation (Clerici, et al., 
2000). 
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Thus resistance among these women is likely due to other factors, such as acquired anti-
HIV immunity (Rowland-Jones, et al., 1998) or other host factors operating in the context 
of the in vivo mileu of the mucosal interface. 
The levels of CCR5 on CD4 T-cells measured in this study were significantly lower than 
has previously been reported in the literature (Paxton, et al., 1998). It is possible that due 
to the fact that we used an anti-CCR5 monoclonal antibody (Mab) conjugated to FITC, 
which is a fairly weak fluorochrome. In order to test this, we conducted a control 
experiment using three samples stained with an anti-CCR5 antibody conjugated to either 
FITC or PE (done by Stephina Nyoka at NIV). The CCR5-PE antibody labeled 
approximately 30% more cells than CCR5-FITC antibody used in the study (Table 3.4.1). 
Thus it is likely that our data are underrepresented by a similar amount. Unfortunately we 
were not able to get fresh blood samples from HEPS sex workers to repeat this 
experiment. Nevertheless, since both HEPS and the control samples were stained with the 
same fluorochrome using the same protocol, our data remain accurate, i.e. there is no 
difference in the numbers of CCR5 positive cells between HEPS and control samples. 
Table 3.4.1: Percentage ofCD4 T-cell positive for CCR5 comparison ofCCR5-PE and CCR5-FITC 
Stephina Nyoka (NIV). 
Sample CCR5-PE 
Sample 1 48.8 
Sample 2 24.2 












HEPS samples used in this study were collected in Durban and shipped overnight to 
Johannesburg. In order to simulate this, control samples that were collected locally were 
left overnight before staining. Previous studies showed that CXCR4 expression is up-
regulated in stored blood samples (Wu, et al., 1997). It is likely that our reported levels of 
CXCR4 are therefore an over-estimate of the true levels. Nevertheless our finding that 
there was no difference between HEPS and control samples in terms of CXCR4 
expression is most likely accurate as all samples were treated similarly. 
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The ~-chemokines RANTES, MIP-la and MIP-1~ have been shown to inhibit replication 
of primary R5 isolates, but not X4 strains of HIV-1 (Cocchi, et al., 1995). It would 
therefore be of interest to quantify ~-chemokines produced by the HEPS PBMC 
compared to amounts produced by a group of PBMC. HEPS PBMC could be protected 
from infection in vivo by high levels of ~-chemokines that could block the binding of 
HIV-1 to the CCR5 coreceptor. 
The infectivity of CD4 T-cells in vitro correlates with the risk of acquiring HIV-1 
infection through sexual exposure. It would thus be expected that a large proportion of 
individuals who are resistant despite multiple sexual exposures would have relatively 
resistant CD4 T-cells. This was not the case among the group of HEPS individuals in this 
study. Cells from these individuals showed a high degree of susceptibility to HIV-1 
infection in vitro. Clearly other mechanisms are in operation to protect these women from 
infection. Studies on similar cohorts have shown that HIV-specific immune responses, 
including mucosal IgA, are present in many of these individuals (Devito, et al., 2000). 
Further studies are needed, particularly at the sites of infection, to determine if strong 
immune responses at the mucosal surface are responsible for protecting these women 
from HIV-1 infection. 
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4.1) INTRODUCTION 
In addition to mutations within the CCR5 gene that abrogate coreceptor function, a number 
of non-coding polymorphisms in the CCR5 promoter region have been identified that that 
may affect the transmission of IDV -1 or the rate of disease progression (McDermott, et al., 
1998). Some of these polymorphisms in the CCR5 promoter region are thought to influence 
the expression levels of IDV-1 coreceptors, which may indirectly influence · the 
susceptibility of PBMCs to HIV -1 viral entry. At least ten single nucleotide polymorphisms 
have been described of which five are most commonly described. These CCR5 promoter 
polymorphisms identified are, CCR5-59029G/A, CCR5-59353T/C, CCR5-59356C/T, 
CCR5-59402G/A and CCR5-59653C/T where the first letter indicates the wild type allele 
and the second the variant. 
In a cohort of IDV-1 seroconvertors lacking both CCR5~32 and CCR2b-64I, individuals 
carrying the CCR5-59029G/G allele progressed to AIDS 3.8 years slower than individuals 
carrying the CCRS-59029 NA allele (McDermot, et al., 1998). When in vitro promoter 
activity was measured using a chloramphenicol acetyltransferase (CAT) reporter system, 
the CCR5-59029G had a lower activity than the CCR5-59029A variant. This implies that 
individuals with the CCR5-59029G allele would have a lower production of rnRNA and 
thus lower levels of CCR5 expression. The CCR5-59029G allele was prevalent in all racial 
groups screened, with an allelic frequency of 43% in whites (n=473), 57% in blacks (n=41) 
and 53% in Asians (n=97) (McDermott, et al., 1998). 
A T-to-C polymorphism at position 59353 was also identified, which was associated with 
prolonged disease progression among IDV-1 infected individuals (Murnmidi, et al., 1998). 
The CCR5-59353C variant always occurred with CCR5-59029A. Individuals with CCR5-
59353T, and not CCR5-59353C had prolonged disease progression either independently or 
in association with CCR5-5929G (Murnmidi, et al., 1998). The promoter activity between 
CCR5-59029N59353C and CCR5-59029G/59353T have been compared in vitro utilising 
the CAT reporter system (McDermott et al., 1998). 
The constructs containing the CCRS 59029N59353C polymorphisms result~d in 45% 
more activation than constructs containing the CCR5-59029G/59353T variants. Another 
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The constructs containing the CCR5-59029A/59353C polymorphisms resulted in 45% 
more activation than constructs containing the CCR5-59029G/59353T variants. Another 
polymorphism in the promoter region, where A substitutes G (CCR5-59402G/A) is thought 
to influence HIV-1 disease progression (Mummidi, et al., 1997), however its functional 
significance has not been confirmed. 
A polymorphism CCR5-59653C/T was identified by Kostrikis et al., (1999) with the 
CCR5-59653T allele which was 100% associated with CCR2b-64I variant. However, in 
another study by Mummidi et al., (1998) the link between CCR2b-64I and CCR5-59653T 
polymorphisms was identified, but in contrast v;ith the report by Kostrikis et al., ( 1999) the 
association between the two polymorphisms was not absolute. HIV-1 infected individuals 
with a CCR5-59653T allele progressed to AIDS or death slower than individuals carrying 
the CCR5-59653C allele (Mummidi, et al., 1998). 
Kostrikis, et al., (1999) identified a polymorphic site in the CCR5 promoter region that 
influences the rate of perinatal HIV-1 transmission among infants born to HIV-1 
infected mothers . To determine the effect of the CCR5-59356T variant in perinatal 
transmission, infants born to AZT (zidovudine) treated and untreated mothers were 
compared. Among the African American infants in the untreated group, there was a 
highly significant increase in HIV-1 transmission to infants with CCR5-59356T/T 
alleles (47.6%), compared to with those carrying none or one mutant allele (13.4 % and 
14.1 %). The CCR5-59356T variant was found to be common among African 
Americans 20.6% (n=552), whereas it was rare among Caucasians 3.4% (n=l 74) and 
Hispanics 5.6% (n=l 13). 
As polymorphisms in the CCR5 promoter region can have a direct or indirect influence 
in HIV-1 resistance, in this study we screened for the prevalence of five CCR5 
promoter polymorphisms in a group of HEPS commercial sex workers (n= l 7). The 
summary of the five CCR5 promoter variants and their effects on HIV-1 pathogenesis 
is presented in Table 4.1. 
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A novel method was developed to screen for point mutations, using fluorescent 
hybridization probes on the LightCycler instrument (Roche, Germany). The reliability 
of this method of detection was ascertained by comparing results to those obtained 
using other conventional methods of genotyping such as PCR-RFLP and sequencing. 
Table 4.1 : CCR5 promoter variants and their effects on HIV-I pathogenesis 
Polymorphisms Effect on HIV-1 pathogenesis Referecnce 





Slows down disease progression McDermott, et al., 1998 
Protects against HIV- I transmission Kostrikis, et al., 1999 
Function unknown Mummidi, et al., 1998 




The prevalence of these polymorphisms m 17 HEPS commercial sex workers were 
compared to a group of HIV-I infected women (n=l3) from the same cohort. Genomic 
DNA was isolated from PBMC using Pure PCR Template Preparation Kit (Boehringer 
Mannheim, Germany) according to the manufacture's instructions (see Appendix Al, 
for details). 
Characteristics of HIV-I seropositive individuals (n= 13), from the same sex workers 
cohort are depicted in Table 2.2.3. These women had seroconverted in the six months 
prior to sample collection. These samples were used to compare the prevalence of the 
CCRS promoter polymorphisms, SDF 1-3 'A and the CCR2b-64I variants to the HEPS 
cohort. 
Table 4.2.1: Characteristics of the acute seroconvertors cohort* 
Sample #Age Partners Condom use Anal sex **Years in 
ID per/wk (%) sex work 
Dull 23 7 >75 No 5.5 
Du21 21 11 25-50 No 6.1 
Du23 19 35 25-50 No 4.1 
Dul04 23 25 25-50 Yes 6.5 
Dul56 35 20 25-50 No 5.6 
Dul72 22 10 25-50 Yes 5.5 
Dul74 28 18 25-50 No 7.5 
Dul79 36 30 25-50 Yes 4.11 
Du258 22 20 25-50 Yes 3.10 
Du368 18 20 25-50 Yes 7.5 
Du422 44 20 50-75 Yes 9.11 
Du457 33 10 25-50 No 5.5 
Du467 26 25 25-50 No 5.11 
*Information provided by Dr. G. Ramjee, (MRC-Durban) 
# Age at time of recruitment (Sep. 1996 - Oct.1997) 
**Years in sex at the time of samples aquisition (Nov. 1999) 
4.2.1 Detection of CCRS promoter polymorphisms by PCR-RFLP. 
a) Detection of CCR5-59029G/ A 
The screening for CCR5-59029G/A variant was performed by PCR-RFLP as described 
by McDermott et al., ( 1998) and compared to fluorescent hybridization probes utilising 
the LightCycler method ( 4.2.3). 
56 
Essentially, a Esp I restriction site is present in the CCR5-59029G allele but absent in 
the CCR5-59029A allele. After PCR using CCR5-59029G/A primer pair (Table 4.2.1), 
the amplicon is digested using Esp I (New England Biotechnology) endonuclease. The 
predicted fragment size for the CCR5-59029A/A was a 275bp fragment, for CCR5-
59029G/G allele 183 and 92bp and for CCR5-59029G/A was 275, 183 and 92bp. 








5 '-GTGGGCTTTTGACT AGA T-' 3 (Reverse) 
5'-ATATTTTCTAACAGATTCTG- '3 (Forward) 
5 '-CCGTTCCCCT ACAAGAAACTCT- '3 (Reverse) 
5 '-AT A TTTTCT AACAGA TTCTG- '3 (Forward) 
5 '-CCGTTCCCCTACAAGAAACTCT-'3 (Reverse) 
5 '-TCATCTGGCCAGAAGAGCTG- '3 (Forward) 
5 '-ACGGTT AT AACA TCAAAGA T-'3 (Reverse) 
Samples were amplified with l.3U Taq polymerase (ICN Biochemicals, USA) in a total 
volume of 20µ1. PCR mixes contained 1.0µ1 ( l.25mM) MgCh, 2.0µ1 1 OX buffer, 2.0µ1 
dNTP (lOmM), 0.5µ1 of each primer at 25pmol/µ1 , 5.0µ1 DNA and made up to 20.0µ1 
with distilled water. Conditions of PCR amplification comprised 2 min denaturation at 
94°C, 35 cycles of 30s at 94°C, 58°C and 72°C, and 1 min final extension at 72°C for 5 
min in a Perkin Elmer 9600 thermocycler. PCR products were digested with Bsp I (New 
England Biotechnology) for 5 hours at 37°C and analysed on a 1.5 % agarose gel, 
electrophoresed in lX TAE (Appendix C3) running buffer and stained with ethidium 
bromide (1 Ong/ml) at a concentration (v/v) of 1µ1/100ml. 
4.2.2 The LightCycler 
a) Principle 
The LightCycler is .a microvolume fluorometer integrated with a thermal cycler that 
combines rapid-cycle DNA amplification with real-time fluorescence monitoring. 
Fluorescence monitoring of amplification is based on the concept that a fluorescence 
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------- - -
between two adjacent fluorescently labeled sequence-specific hybridization probes 
(Wittwer, et al. , 1997). 
The two probes are designed to hybridize to the same strand between two unlabeled 
primers. One of the probes is labeled at the 3' end with fluorescein and the other probe 
is labeled at the 5' end with a LightCycler red fluorophore (LC-Red 640). The anchor 
probe was labeled with LC-Red-640 on the 5' end and phosphorylated on the 3' end to 
prevent probe elongation. The sensor probe was labeled with fluorescein on the 3' end. 
After hybridization, the two probes are in close proximity, which allows fluorescent 
energy transfer between these fluorophores. The donor fluorophore , fluorescent (FLU) 
is excited by the light source of the instrument, and part of the excitation energy is 
transferred to LightCycler Red 640 (LC-Red 640), an acceptor fluorophore . The 
emitted fluorescence is measured and is proportional to the amount of specific target 
sequences in the reaction mixture. With an appended melting curve analysis of the 
obtained amplification products, the method is suitable for mutation detection 
(Mangasser-Stephan, et al., 1999). 
4.2.3) Detection of CCRS Promoter Polymorphisms by fluorescent 
hybridization probes on the LightCycler 
Screening for CCR5-59353T/C, 59402G/A and 59653C/T variant was done using the 
fluorescent hybridization probe method. Forward and reverse primers (Table 4.2.1) 
were used to amplify DNA together with hybridization probes to detect point mutations 
(Table 4.2.2). PCR and point mutation detections were performed in 20µ1 volumes in 
glass capillaries (Boehringer Mannheim, Germany). For all the point mutation 
detections the following protocol was followed : 6.4µ1 H20, 2.0µ1 MgCh (2.5mM), 
1.0µ1 Primer at 25pMol/µl each, 1.3µ1 (0.006µM) of each hybridization probe (TIB 
MOLBIOL, Germany) 2.0µ1 of DNA-Master Hybridization Probes (Roche, Germany) 
containing Taq DNA polymerase, reaction buffer, dNTP mixture and lOmM MgCh as a 
1 OX concentrate. Five micro litres of genomic DNA (20-200ng) was used as template. 
Fluorescently labelled hybridization probes were synthesized by TIB MOLBIOL 
(Germany). 
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Five micro litres of genomic DNA (20-200ng) was used as template. Fluorescently 
labelled hybridization probes were synthesized by TIB MOLBIOL (Germany). 
Cycling conditions were as follows; 95°C for 1 Omin (activation), 45 cycles at 95°C for 
10 seconds, 55°C for 10 seconds and 72°C for 12 seconds with a ramping time of 
20°C/s. After amplification, melting curves were generated following denaturation of 
the PCR product. The melting curves protocol followed was denaturation at 95°C for 10 
seconds, annealing at 40°C for one minute and then slowly heating the samples to 95°C 
with a ramp rate of 0.2°C/s and simultaneous monitoring fluorescence decline. Melting 
curves were converted to melting peaks by plotting the negative derivative of the 
fluorescence with respect to temperature (-dF/dT) against time. The wild type allele 
produced specific peaks which differed in melting temperature (Tm) to those of the 
mutant allele. 
a) Detection of CCR5 59029G/A 
In addition to the PCR-RFLP method, CCR5-59029G/A was also genotyped using 
fluorescent labelled hybridization probes. CCR5-59029G/ A primers (Table 4.2.1) were 
used to amplify DNA, and two hybridization probes, the anchor probe CCR5-029(A) 
and the sensor probe CCR5-029(S) were included (Table 4.2.2). 
Table 4.2.2 : Hybridization probes used in the detection of point mutations. 
Name Probe Sequence 
CCR5-029(A) 5 ' -LC-Red 640-CACTCTCCCCGT A TCCCCT A TCCCAC-P 





(A) = Anchor probe 
(S) = Sensor probe 
5'-LCRed640-GATCTATTCTCTAGCTTATTTTAAGCTCAAC-P 
5'-CCGTAAATAAACTTTCAGACCA-'3 
5 '-LC-Red 640-CAAACACCAAGTGCTCA T ACAA TT A TC-3 ' -P 
5'-GGAAACCCATAGAAGACATTTG-'3-FLU 
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b) Detection ofCCRS-59353 TIC 
The CCR5-59353T/C variant was genotyped using fluorescent hybridization probes, 
and the results were ascertained by sequencing. CCR5-59353T/C primers (Table 4.2.1) 
were used to amplify DNA, hybridization probes CCR5-353(A) and CCR5-353(S) 
(Table 4.2.2) were used for genotyping for the CCR5-59353T/C variant. 
c) Detection of CCRS 59402 GI A 
The CCR5-59402G/A variant was genotyped usmg fluorescent hybridi zation probes, 
results were ascertained by sequencing using CCR5-59402G/A primers (Table 4.2.1 ). 
d) Detection of CCR5-59653C/T 
The CCR5-59653C/T variant was genotyped using fluorescent hybridization probes 
method . CCR5-59653C?T primers (Table 4.2.1) were used together with the CCR5-
653(A) and CCR5-653(S) hybridization probes (Table 4.2.2) . 
4.2.4 Sequencing 
A 297bp fragment between 59272 and 59569 bases of the CCRS promoter region as 
numbered in the GenBank (U95626) was sequenced. The fragment included three 
known polymorphic sites, CCR5-59353T/C, CCR5-59356C/T and CCR5 -59402G/A. 
Sequencing was performed by Mr Peter Owira of the Department of Medica l 
Microbiology U.C.T us ing the ABI Prism 310 Genetic Analyzer (Perkin Elmer). The 
forward and the reverse strands were aligned and compared to a published sequence. 
Polymorphi sms were identified by analysis of aligned sequences using the Auto 
Assembler 2.1 package of the Prism 310 Genetic Analyzer. 
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c) Detection of CCRS 59402 GIA 
The CCR5-59402G/A variant was genotyped usmg fluorescent hybridization probes, 
results were ascertained by sequencing using CCR5-59402G/A primers (Table 4.2. l ). 
d) Detection of CCR5-59653C/T 
The CCR5-59653C/T variant was genotyped usmg fluorescent hybridization probes 
method. CCR5-59653C/T primers (Table 4.2.1) were used together with the CCR5-
653(A) and CCR5-653(S) hybridization probes (Table 4.2.2). 
4.2.4 Sequencing 
A 297bp fragment between 59272 and 59569 bases of the CCRS promoter region as 
numbered in the GenBank (U95626) was sequenced. The fragment included three known 
polymorphic sites, CCR5-59353T/C, CCR5-59356C/T and CCR5-59402G/ A. 
Sequencing was performed by Mr Peter Owira of the Department of Medical 
Microbiology U.C.T using the ABI Prism 310 Genetic Analyzer (Perkin Elmer). The 
forward and the reverse strands were aligned and compared to a published sequence. 
Polymorphisms were identified by analysis of aligned sequences using the Auto 
Assembler 2.1 package of the Prism 310 Genetic Analyzer. 
Figure 4.2.1 is the schematic representation of the CCRS gene including the promoter 
region (Kostrikis, et al., 1999). The promoter region lies upstream of the 5' end of the 
exon four of the CCR5 gene. Appendix AS depicts the actual CCRS promoter sequence, 
the position of the primers and the position of the probes used to screen the CCR5 
promoter polymorphisms in the study. 
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Fig. 4.2.1 : Schematic representation of the geno mic o rga niza tio n of the CCR2 and CCR5 genes on chromosome 3 and loca tions of polymorphic si tes in the regulatorv 
,cgion of CCR5 (59029-G/A. 59353-T/C. 59356-C/T. and 59402-NG ) and in the coding regions of CCR5 (l'>32) and CCR2 (C,4 1) ge ne,. Open hoxes 111d1catc noncod mg 
.:xons and open reading frames (ORF); lines signify int rans. Exons and mutatio ns arc numbered based on the nucleotide position of th e unpuhlished sequence wnh 
GenBank accession no. U95626. For each CCR5 polymorphism. the fi rs t lett er indica tes the wild -type nucleotide and the ,econd indica tes the mutant nucleotide. 
59 
4.3) RESULTS 
The fluorescent hybridization probe method was developed to screen single base pair 
nucleic acid changes in the CCR5 promoter region. This method was compared to 
sequencing to detect the CCR5-59353T1C variants. The hybridization probes had 
different melting temperatures (Tm) depending on the sequence (Fig. 4.3. l ). For 
samples homozygous for T variant had one peak with a Tm of 57°C and homozygotes 
C had one peak at a Tm of 52°C clearly differentiating the two alleles. Heterozygotes 
had two peaks at Tm of 57°C and 52°C. These results were confirmed by sequencing 
analysis where homozygotes yielded one peak on the chromatogram and 
heterozygotes two peaks at the same position . 
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Fig. 4.3.1 : A representative graph illustrating the shift in melting curves due to point mutation in 
CCR5-59353T/C. The melting temperature (Tm) of the sensor probes are shown. Tm for 59353 TIT is 
57°C, Tm for 59353 C/C is 52°C and Tm for 59353 T/C is 57°C and 52°C. 
This correlation, along with large differences in melting temperature between the two 
probes, indicated that fluorescent hybridization probes were a reliable method for 
detection of point mutations (Table 4.3.1). Using this method six samples were found 
to carry the CCR5-59353T/T variant, eight carried the CCR5-59353TIC and three had 
the CCR5-59353CIC variants, resulting in an allelic frequency of 59% among the 17 
HEPS women. 
Among a group of HIV-1 infected women (n=13) used as a comparative group, three 
samples carried the TIT variant, five had the TIC and seven the CIC variants resulting 
in an allelic frequency of 39%. 
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Table 4.3.1 : Different methods used to detect point mutations in the CCR5 promoter region 
Gene Variant Method of detection 
PCR-RFLP Hybridization Sequencing 
CCRS-59029 
GIG 6 7 ND 
GIA 9 8 ND 
A/A 2 2 ND 
CCRS-59353 
Tff ND 6 6 
TIC ND 8 8 
CIA ND 3 3 
CCRS-59402 
GIG ND ND 6 
GIA ND ND 8 
AIA ND ND 3 
CCRS-59653 
CIC ND 12 ND 
err ND 4 ND 
Tff ND ND 
However, when this method was compared with PCR-RFLP for detection of the 
CCR5-59029G/A variant, there was one discrepancy. RFLP detected a G to A base 
change through the elimination of a Bsp I restriction site in CCR5-59029A/A allele. 
The CCR5-59029A/A produced a band of 275bp, the CCR5-59029G/A produced 
bands of 275bp, 183bp and 92bp, and the CCR5-59029G/G produced bands of l 83bp 
and 92bp. A typical gel electrophoresis result of this variant is depicted in Fig. 4.3.2. 
Among the HEPS population six samples were found to carry the CCR5-59029G/G 
variant, nine carried the CCR5-59029G/A variant and two had the CCR5-59029A/A 
variant (Table 4.3.1 ). The discrepancy could be attributed to a partial digest by the 
restriction enzyme resulting in nine instead of eight 59029G/A alleles detected by 
PCR-RFLP. 
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2 3 4 5 G 7 8 9 10 11 12 13 14 15 16 17 M 
Fig. 4 .3.2 : Agarose ge l illustrating the result of th e PCR-RFLP anal ysis for CCR5-59029G/A . CCR5-
59029G/G ill ustrated in (lanes 6,7,8, 11,12 , 13), CCR5-59029G/A (lanes l,2,4,9,10,14,15,16,17) and CCR5-
59029A/A (3 and 5). 
Given the clear differentiation of melting curves (Fig. 4.3.3), samples homozygous for 
CCR5-59402G variant had one peak with a Tm of G8 °C and homozygotes CCRS-59402A 
had one peak at a Tm of G l °C and CCRS-59402G/A (heterozygotcs) had two peaks at 
Tm of 68°C and G l 0 C. The PCR-RFLP method has previously been shown to produce 
fal se positive (Chapter 2), the fluorescent hybridization probe method has been shown to 
be a more reliable method of detection and it was therefore applied to detect the CCRS-
59653C/T. 
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Fig. 4.3.3 : A representative graph illust ratin g the sh ift in melting curves due to point mutation in CCR5-
59029G/A. The melting temperature (Tm) of the sensor probes are shown. Tm for 59029G/G is 68°C, Tm 
fo r 59029A/A is 60.8°C and T m fo r 59029G/A is 68°C and 60.8°C. 
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Twelve samples were found to carry the CCR5-59653C/C variant, four carried the 
CCR5-59653T/C and only one had the CCR5-59653T/T variant, resulting in an allelic 
frequency of 18% among the 17 HEPS women, a typical graph is depicted in Fig. 
4.3.4. The allelic frequency of this variant was higher (27%) among the HIV-1 
infected women, seven women had the CCR5-59653T/T variant, five carried CCR5-
59653T/C and only one had the CCR5-59653T/T variant. The above data indicate that 
the fluorescent hybridization probe method, the preferred method for genotyping, 
once optimised it is more robust, reliable and quicker. 
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Fig. 4.3.4 : A representative graph illustrating the shift in melting curves due to point mutation in 
CCR5-59653Cff The Tm of the individual detection probes are shown. Tm for 59653C/C is 56.7°C, 
Tm for 59653 Tff is 48°C and Tm for 59653 err is 56.7°C and 48°C. 
However, difficulty was experienced in designing certain probes such as probes to 
detect the CCR5-59402G/A variant. The CCR5-59402G/A and CCR5-59356C/T 
variants were both detected by sequencing in the HEPS population. All 17 women 
carried the wild type allele CCR5-59356C, and for the CCR5-59402G/A, six had the 
CCR5-59042G/G variant, eight carried the CCR5-59402G/A and three the CCR5-
59402A/A variant. Absolute linkage was observed between CCR5-59353T/C and 
CCR5-59402G/A, with six women carrying both CCR5-59353T/T and CCR5-
59402G/G, 
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eight carrying both CCR5-59353T/C and CCR5-59402G/A and three with CCR5-







































Fig. 4.3.5 : Sequence analysis of the CCR5 promoter region between the bases 59342 and 59381 
(GenBank U 95626) including the polymorphic sites 59353T/C (Red) and 59356C/T (Green) A, and 
B 59402G/A polymorphic site (Blue) found between the bases 59382-59421. 
G5 
Of the 17 HEPS samples genotyped by fluorescent hybridization probe method, 
seven carried the CCRS-59029 GIG variant, two had the CCR5-59029NA and eight 
had the CCR5-59029G/A variant. A typical graph showing results of different 
alleles genotyped by the fluorescent hybridization probe is depicted in Fig. 4.3.3. 
The allelic frequency of 60% was obtained for the CCR5-59029G variant compared 
to 62% among HIV-I infected women (Table 4.3.2). 
Table 4.3.2 : Allelic frequencies of CCR5 promoter polymorphisms observed in the study population. 










































CIC 12 7 ND 
err 4 s ND 
Tff I I ND 
Allelic frequency(%) (T) 18 27 ND 
'Easterbrook, et al., ( 1999). Study done on a population of non-progressors from a cohort in the United Kingdom. 
(ND = not done). 
Table 4.3.2 depicts the allelic frequencies of the four CCR5 promoter polymorphisms 
· studied in HEPS and HIV-1 infected women from the same cohort, compared to a 
group of non-progressors. Elevated frequencies were observed for the CCR5-59353T 
and the CCR5-59402G variants (59%) among the HEPS population compared to 39% 
found in the HIV-1 infected women. The allelic frequency of the CCR5-59029A variant 
was found to be lower lower (35%) among the HEPS women compared to the HIV-I 
infected women (38%). An elevated allelic frequency was observed among the HIV-I 
infected women (27%) compared to HEPS women (18%) for the CCR5-59653T 
variant. 
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Unlike McDermott (1998) who showed absolute linkage between CCR5-59029G and 
CCR5-59353T, in this study eight individuals who had the CCR5-59029G/A variant 
also carried the CCR5-59353T/C variant. However, of seven individuals carrying the 
CCR5-59029G/G only six had the CCR5-59353T/T variant. Three individuals carried 
the CCR5-59353C/C and only two carried the CCR5-59029A/A (Table 4.3.3). 
There was absolute linkage between the CCR5-59353T/C and CCR5-59402G/A 
variants. Six individuals who had the CCR5-59353T/T variant also had the CCR5-
59402G/G variant, eight individuals had both the CCR5-59353T/C and CCR5-
59402G/A variants, finally three individuals had both CCR5-59353C/C and CCR5-
59402A/A variants (Table 4.3.3). 
Table 4.3.3 : Linkage among CCR5 promoter polymorphisms in the HEPS women. 
Sample ID 59029 59353 59353 59402 
Du4 GIA TIC TIC GIA 
Du6 GIA TIC TIC GIA 
Du7 GIG TIT TIT GIG 
Du20 GIA TIC TIC GIA 
Du53 GIG TIT TIT GIG 
Du85 GIA TIC TIC GIA 
Du96 GIA TIC TIC GIA 
Dul17 GIA TIC TIC GIA 
Dul26 GIG TIT TIT GIG 
Du154 GIG TIT TIT GIG 
Du175 GIG TIC TIC GIA 
Du188 GIA TIC TIC GIA 
Du205 GIA CIC CIC NA 
Du250 GIG TIT TIT GIG 
Du270 NA CIC CIC NA 
Du272 GIG TIT TIT GIG 
Du366 NA CIC CIC NA 
The strong linkage between the CCR5-59029G/A and the CCR5-59353T/C variants 
was also observed among the IIlV-1 infected women. Two individuals who carried the 
CCR5-59029G/A variant also carried the CCR5-59353T/C variant, four individuals 
who had the CCR5-59029G/G variant also had the CCR5-59353T/T variant and two 
individuals who carried both the CCR5-59029A/A and CCR5-59353T/T variants 
(Table 4.3.4). 
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Table 4.3.4: Linkage among CCR5 promoter polymorphisms in HVI-1 infected women. 
Sample ID 59029 59353 
Dull GIA TIC 
Du21 GIA TIC 
Du23 GIA CIC 
Dul04 GIA CIC 
Du156 GIG T!T 
Du172 NA CIC 
Du174 GIG TIC 
Du179 GIG T!T 
Du258 GIA CIC 
Du368 GIG T!T 
Du422 GIA CIC 
Du457 NA CIC 
Du467 GIG T!T 
4.4) DISCUSSION 
This is the first study looking at the frequency of promoter polymorphisms in South 
African Populations. The allelic frequency for the CCR5-59029A variant in the 
HEPS population (35%) was lower compared to the HIV-1 infected group (38%). 
Although other studies have reported a linkage between the CCR5~32 mutation and 
the CCR5-59029A variant (McDermott, et al., 1998), this was not observed in the 
current study, as none of the 17 HEPS women had the CCR5~32 mutation (Chapter 
2). Although the CCR5-59029G variant and the CCR5~32 mutations have been 
associated with delayed disease progression and protection from infection, the 
protective effect of CCR5-59029G relative to CCR5-59029A was found to be 
independent of any protection conferred by CCR5~32 mutation (McDermott, et al., 
1998). This is important especially to Africans who lack the CCR5~32 mutation. 
An elevated frequency for CCR5-59353T (59%) in the HEPS population was 
observed compared to HIV-1 infected women (39%). There was a strong linkage 
between CCR5-59029G and CCR5-59353T variants in this study. But unlike other 
studies the linkage was not absolute. This study showed absolute linkage between 
CCR5-59353T and CCR5-59402G which has never been previously reported. 
The allelic frequency for CCR5-59653T was higher in the HIV-1 infected group 
(27%) compared to the HEPS population (18%). The CCR5-59653T variant is 
associated with delayed disease progression (Clegg, et al., 2000). In this study, two 
out of the three HEPS women who were heterozygous for CCR2b-64I were also 
found to carry the CCR5-59653T variant, an association previously identified by 
Kostrikis, et al., (1998). 
This study provides evidence of the polymorphic nature of the CCR5 gene and its 
possible implications in resistance to infection. This study also highlights the high 
level of linkage among CCR5 promoter variants. Some of the polymorphisms 
associated with HIV-1 di sease may not be directly responsible for the clinical 
effects but are associated via linkage with other mutations or polymorphisms. 
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Two variants CCR5-59353T and CCR5-59402G, which were previously been 
identified to be associated with increased survival were also found in higher 
frequencies in the HEPS population compared with the HIV-1 infected group. It 
would be of interest to extend this study to include a large population to get more 
accurate data on background frequency. 
Although the CCR5-59356T variant has not been reported to affect the transmission 
of HIV-1 by sexual intercourse, it was linked to increased risk of perinatal 
transmission. This variant was not identified in this study group and its role if any in 
HIV-I transmission by sexual intercourse needs to be investigated. 
Polymorphisms in the CCR5 promoter region are hypothesized to mediate the wide 
variation in CCR5 expression levels thereby influence HIV-1 disease progression. 
Identification of the functionally active polymorphisms and the mechanisms by 
which they mediate their effects will be an important step in identifying potential 
treatment targets, devising new strategies for slowing the progression of HIV-1 to 




The complexity of interpreting the impact of host polymorphisms on resistance 1s 
illustrated by the extent of linkage between genetic changes (Table 5 .1 ), as well as the as 
well as variation in their frequency within different populations (Figure 5.2). No 
mutations associated with HIV-1 resistance (CCR5~32 and CCR5m303) were detected in 
the CCR5 coding region in any of the HEPS women screened. However, an elevated 
frequency in the SDF1-3'A variant was observed among the HEPS compared to the 
background population (Figure 5.1). The role of SDF1-3'A is uncertain as SDF it is the 
ligand for CXCR4 receptor, a receptor not associated with transmission. Further work 
needs to be done to understand the role of this mutation as controversial results have also 
been obtained in looking at its relationship to disease progression. Studies have shown 
this variant to delay disease progression (Winkler, et al., 1998), while other studies have 
shown this variant to be associated with accelerated disease progression (Brambile, et al., 
2000). It is possible this mutation is acting as a marker for another biologically relevant 
mutation. It would be of interest include quantifying the levels of chemokines in the 
study population, since elevated chemokines have been reported to prevent HIV-1 
infection. 
For the HIV-1 virus to infect PBMCs it requires both the CD4 marker and a coreceptor. 
In the current study, all PBMCs tested were infectable by RS, R5X4 and X4 viral strains. 
This data confirmed with the genotyping results that revealed all samples are carrying the 
wild type CCR5 variant, furthermore the ability of PBMCs to support viral replication is 
indicative of functional chemokine receptors. Studies have shown that using low titre of 
virus, it is possible to identify low levels of resistance to infection (Castillo, et al., 2000). 
It would be of interest to apply this method to PBMCs from HEPS to determine if there 
are more subtle levels of resistance that were not being detected when challenging with 
high titres of viral stocks. 
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The level of chemokine receptor expression levels are a determining factor in infection, it 
has been show that individuals who have high levels of expression are easily infected 
compared to individuals who have lower levels of chemokine receptors. The expression 
levels of chemokine receptors are also a manifestation of the genotype, individuals 
carrying the CCR5 allele express more levels of the chemokine receptor than individuals 
carrying the CCRS.6.32 variant. In this study all HEPS women had the wild type CCR5 
allele, however, an apparent increase in frequency of certain promoter polymorphisms 
were identified. These polymorphisms have been reported to delay disease progression 
and do not appear to affect HIV-1 infection. However, it is possible that they may 
contribute to resistance by affecting levels of CCR5 expression. This study needs to be 
extended to determine the background frequency of promoter polymorphism in the South 
African population. 
In conclusion, the precise mechanisms responsible for resistance to HIV-1 infection 
remains unclear. It is apparent that resistance is not absolute as there are women in this 
and other similar cohorts who seroconverted after being many years in sex work. It is 
possible that there are certain host genetic mutations that give some women the 
advantage over others. These could be CCR5 promoter polymorphisms which affect 
levels of expression or other as yet undiscovered polymorphisms. It is also probable that 
resistance is not due to one factor, but a combination of factors, and that immunological 
responses will impact on resistance. 
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Table5.1 : Summary of all genetic polymorphism detected in for each women. 
Sample Number of Host Genetic Variants Associated with HIV-1 Pathogenesis 
ID years in sex 
work 














































CCR5~2 CR5m303 CCR2b-64I SDF1-3'A 590229 59353 59356 
wt/wt wt/wt wt/wt wtM GIA TIC CIC 
wt/wt wt/wt wt/wt wt/wt GIA TIC CIC 
wt/wt wt/wt wt/wt wt/wt GIG TIT CIC 
wt/wt wt/wt wt/wt wtM GIA TIC CIC 
wt/wt wt/wt wt/wt wt/wt GIG TIT CIC 
wt/wt wt/wt wt/vt wt/wt GIA TIC CIC 
wt/wt wt/wt wtM wt/wt GIA TIC CIC 
wt/wt wt/wt wtM wt/wt GIA TIC CIC 
wt/wt wt/wt wt/wt wt/wt GIG TIT CIC 
wt/wt wt/wt wt/wt wt/wt GIG TIT CIC 
wt/wt wt/wt wt/wt wt/wt GIG TIC CIC 
wt/wt wt/wt wt/wt wt/wt GIA TIC CIC 
wt/wt wt/wt wt/wt wt/wt GIA CIC CIC 
wt/wt wt/wt wt/wt wt/wt GIG TIT CIC 
wt/wt wt/wt vt/vt wt/wt A/A CIC CIC 
wt/wt wt/wt wt/wt wt/wt GIG TIT CIC 
wt/wt wt/wt wt/wt wt/wt A/A CIC CIC 
CCR5M303 CCR2b-64I SDF1-3'A 
Fig. 5.1 : Chemokine and chemokine receptor allelic frequencies identified in HEPS women and in the 





























59029A 59353T 59402G 59653T 
Fig. 5.2 : Frequencies ofCCR5 promoter polymorphsms identified in HEPS women, HIV-1 infected 
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APPENDIX A : DNA TECHNIQUES 
A.1 DNA extraction 
DNA was extracted from PBMC by Pure PCR Template Preparation Kit (Boehringer 
Mannheim, Germany) according to the manufacturer's instructions. Blood sample 
(200µ1) was added to equal volume of binding buffer, and 40µ1 of proteinase K was 
added and mixed. Incubated for 10 minutes at 72°C. Isopropananol ( 100µ1) was added 
and the whole mixture added into combined high pure filter tube and centrifuged for a 
minute at 200g force. The column was washed twice with 500µ1 of wash buffer. DNA 
was eluted with 200µ1 of prewarmed (70°C) elution buffer. DNA aliquats (20µ1) were 
stored at -20°C. 
A.2 PCR protocols 
a) CCR5D.32 detection 
The CCR5 gene was amplified by CCR5-F and CCR5-R primers (Table 1) in order to 
detect the CCR5D.32 polymorphism. A band of 225bp was generated for the CCR5 (w/w) 
wild type variant. The PCR master mixes (20µ1) contained the following : 
* 2.5µ1 lOX PCR buffer 
* 2.0µ1 of lOmM dNTP's 
* 2.0mMMgCh 
* 1.0µ1 of each primer (25pmol/µl) 
* 5U/µ1 of Taq DNA polymerase 
The reaction mixes were made up to 20ul with sterile water and 5.0µ1 of sample DNA 
added. 5µ1 of sterile water was added instead of sample DNA for the negative control. 
Amplification conditions in the Perkin-Elmer 9600 thermocycler: 
* Initial denaturation at 95°C for 2 minutes 
* 95°C for 30 seconds, 60°C for 30 seconds and 72°C for 30 seconds (30 cycles) 
* Final extension at 72°C for 5 minutes 
Agorose gel electrophoresis was used for the analysis of the PCR product. 
b) CCR5m303 detection 
The CCR5-m303 gene was amplified by CCR5-m303(F) and CCR5-m303(R) primers 
(Table 1) in order to detect the CCR5-m303 polymorphism. A band of 350bp was 
generated by PCR for RFLP analysis. The CCR5-m303 (w/w) wild type variant 
generated bands of 230 and 120bp. The PCR master mixes (20µ1 ) contained the 
following: 
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* 2.5µ1 lOX PCR buffer 
* 2.0µ1 of lOmM dNTP's 
* l .5mMl MgCh 
* 1.0µ1 of each primer (25pmol/µl) 
* 5U/µl of Taq DNA polymerase 
The reaction mixes were made up to 20ul with sterile water and 5.0µ1 of sample DNA 
added. 5µ1 of sterile water was added instead of sample DNA for the negative control. 
Amplification conditions in the Perkin-Elmer 9600 thermocycler: 
* Initial denaturation at 94°C for 2 minutes 
* 94°C for 20 seconds, 58°C for 20 seconds and 72°C for 40 seconds (30 cycles) 
* Final extension at 72°C for 6 minutes 
Restriction endonuclease digestion , 
The restriction digest was carried out as described in Sambrook, et.al (1989). The 
following were added for a single digestion reaction : 
* 2.5µ1 restriction endonuclease buffer (lOX) (Boerhinger Manheim, Germany) 
* 0.5µ1 (500U/µl) Hine II (Boerhinger Manheim, Germany) 
*2.0µ1 sterile water 
The 5.0µ1 mix was added to the 20.0µl PCR product and incubated for 4 hours at 37°C. 
Agorose gel electrophoresis was used for the analysis of the PCR-RFLP product. 
c) SDF1-3'A detection 
The SDF-1 gene was amplified by SDF-l(F) and SDF-l(R) primers (Table 1) in order to 
detect the SDF1-3'A polymorphism. A band of 303bp was generated by PCR for RFLP 
analysis. The SDF-1 (w/w) wild type variant generated bands of 179 and 124bp, the 
homozygote mutant (SDF1-3'A/ SDF1-3'A) allele produced a band of 303bp and the 
heterozygote produced bands of 303, 175 and 112bp. The PCR master mixes (20µ1) 
contained the following : 
* 2.5µ1 lOX PCR buffer 
* 2.0µ1 of lOmM dNTP's 
* l .5mM MgCh 
* 1.0µ1 of each primer (25pmol/µl) 
* 5U/µl of Taq DNA polymerase 
The reaction mixes were made up to 20ul with sterile water and 5.0µ1 of sample DNA 
added. 5µ1 of sterile water was added instead of sample DNA for the negative control. 
Amplification conditions in the Perkin-Elmer 9600 thermocycler : 
* Initial denaturation at 94°C for 2 minutes 
* 94°C for 30 seconds, 65°C for 30 seconds and 72°C for 30 seconds (30 cycles) 
* Final extension at 72°C for 6 minutes 
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Restriction endonuclease digestion , 
The restriction digest was carried out as described in Sambrook, et.al (1989). The 
following were added for a single digestion reaction : 
* 2.5µ1 restriction endonuclease buffer (lOX) (Boerhinger Mannheim) 
* 0.5µ1 (1,000U/ml) Msp I (Boerhinger Mannheim, Germany) 
*2.0µl sterile water 
The 5.0µ1 mix was added to the 20.0µl PCR product and incubated for 4 hours at 37°C. 
Agorose gel electrophoresis was used for the analysis of the PCR-RFLP product 
d) CCR2b-64I detection 
The CCR2b gene was amplified by CCR2b(F) and CCR52b(R) primers (Table 1) in ord·~r 
to detect the CCR2b-64I polymorphism. A band of 183bp was generated by PCR for 
RFLP analysis. The CCR2b (w/w) wild type variant generated a band of 183bp, the 
homozygote mutant (641/641) allele produced bands of 165 and 18bp and the 
heterozygote produced bands of 183, 165 and 18bp. The PCR master mixes (20µ1) 
contained the following : 
* 2.5µ1 lOX PCR buffer 
* 2.0µ1 of lOmM dNTP's 
* 2.0mMMgCh 
* 1.0µ1 of each primer (25pmol/µl) 
* 5U/µl of Taq DNA polymerase 
The reaction mixes were made up to 20ul with sterile water and 5.0µ1 of sample DNA 
added. 5µ1 of sterile water was added instead of sample DNA for the negative control. 
Amplification conditions in the Perkin-Elmer 9600 thermocycler : 
* Initial denaturation at 94°C for 2 minutes 
* 94°C for 20 seconds, 53°C for 20 seconds and 72°C for 20 seconds (5 cycles) 
* 94°C for 20 seconds, 63°C for 20 seconds and 72°C for 20 seconds (25 cycles) 
* Final extension at 72°C for 6 minutes 
Restriction endonuclease digestion , 
The restriction digest was carried out as described m Sambrook et. al (1989). The 
following were added for a single digestion reaction : 
* 2.5µ1 restriction endonuclease buffer (lOX) (Separations) 
* 0.5 µI ( l ,OOOU/ml) BSaB I (Separations) 
*2.0µ1 sterile water 
The 5.0µ1 mix was added to the 20.0µ1 PCR product and incubated for 1 hour at 60°C. 
Agorose gel electrophoresis was used for the analysis of the PCR-RFLP product. 
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A.3 Electrophoresis 
Agarose gel electrophoresis was performed as described in Sambrook, et al., (1989). The 
agarose powder was melted with frequent swirling to prevent clumping in lX T AE at 
concentrations of one to 2.5%, depending on the size of the DNA fragments to be 
separated. Once melted, ethidium bromide ( 1 Ong/ml) stain was added to a final 
concentration of 1ug/100ml of agarose. The agarose gel slabs were allowed to set at room 
temperature for 30-60 minutes after which the well combs were removed. Samples were 
mixed with 1/5 their volume of loading dye and added to the lX TAE submerged wells. 
The agarose gel was electrophoresed at 85V for an hour until the fragments were 
separated. The DNA fragments were then visualised using the ultraviolet transilluminator 
box and photographed with the computerised gel imager by Kodac digital SciencelD-
camera. Molecular weight marker VI (Boerhinger Mannheim) was used to determine 
DNA fragment size. 
Fig. 1: Marker VI 
VI 
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A.4 LightCycler 
a) Product Description 
Light Cycler (LC) System is a fast PCR amplification and analysis system. Central to the 
function of the LC system are the use of air as a medium for heating and cooling and the 
use of capillaries as reaction vessels for efficient temperature exchange between the air 
and the reagents in the capillary. The capillaries are made of borosilicate glass. 
Fluorescence data is recorded by the optical unit of the instrument and are displayed on a 
computer screen as PCR proceeds and are stored for further analysis. 
!'?. ach e J'Vl o l ecular I -Jiucl, c n1ica / s 
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Fig. 3: Schematic representation of the working components of the LightCycler. 
b) Principle 
The Hybridization Probes format is a fluorescent format used as a reporter in the LC 
system. The Hybridization Probes, labelled with two different fluorescent molecules, 
hybridize next to each other on the target DNA molecule. The first fluorescent dye, the 
donor dye fluorescein, is excited at 470nm by the light source of the LC instrument. 
Instead of emitting light at 530nm, the fluorescein can transfer its energy in a non-
fluorescent manner to an acceptor dye, LightCycler-Red 640(LC-Red 640) in a process 
called Fluorescence Resonance Energy Transfer (FRET). 
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The principle behind point mutation detection, is based on the usage of two distinct 
hydridization probes (short oligonucleotides). One hydridization probe matches the wild-
type sequence with the variable nucleotide in the middle of the sequence, and has LC-
Red640 as the fluorophore at its 5' end (sensor probe), a second hybridization probe 
(anchor probe) is located upstream at a distance of one nucleotide and is labelled with 
fluorescein at its 3' end. After hybridization, the two probes are in close proximity, which 
allows fluorescence energy transfer between the fluorophores. The donor fluorophore 
fluorescein is excited by the light source of the instrument, and part of the excitation 
energy is transferred to LC-Red 640, an acceptor fluorophore. 
Upon completion of PCR, the PCR product is denatured, then the temperature is lowered 
to 40°C to facilitate binding of the hybridization probes, thus generating maximum 
fluorescence, and slowly raised to 95°C to permit melting of the detection probe, which is 
monitored by the decline of the fluorecence. Melting curves are automatically converted 
to melting peaks, allowing easy distinction of wild type from mutant allele. The distinct 
peaks are specific to either allele (wild or mutant) and are indicative of the temperature at 
which the sensor probe is detached from the PCR template. 
c) Point mutation detection protocol 
The CCR5 promoter polymorphisms were detected by LC and each allele was 
characterised by a specific melting temperature (Tm). 
The PCR master mixes (20µ1) contained the following : 
* 1.3 µl of each hybridization probe (0.006µmol/µl) (Table l) 
* 2.0mMMgCh 
* 1.0µ1 of each primer (25pmol/µl) (Table 1) 
* 2.0µ1 of master mix (Taq DNA polymerase, reaction buffer, dNTP mixture 
and 1 OmM MgCh as a 1 OX concentrate) 
The reaction mixes were made up to 20µ1 with sterile water and 5.0µ1 of sample DNA 
added. 5µ1 of sterile water was added instead of sample DNA for the negative control. 
Amplification conditions were as follows : 
* Activation; 95°C for 10 minutes 
* PCR; 95°C for 10 seconds, 45°C for 10 seconds and 72°C for 12 seconds (42 
cycles) 
* Melting; 95°C for 1 minute, 40°C for 1 second and to 95°C at a rate of 0.2°C 
* Cooling at 40°C for 2 seconds 
The resulting melting curves were converted to melting peaks and used to determine the 
melting temperatures (Tm), each peak characteristic of a particular allele variant. 
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The resulting melting curves were converted to melting peaks and used to determine the 
melting temperatures (Tm), each peak characteristic of a particular allele variant. 
Table 1 : Probes and primers used for point mutation detection on the LightCycler 
Variant Primer Pair (25pmoV) Probe Pair (0.006 lmoll I) 
59029 GIA 5 -GTGGGCTITIGACTAGAT- 3 5-LC-Red 640-CACTCTCCCCGTATCCCCTATCCCAC- 3p 
5-TTCCGTTTACAGAGAACAATA-3 5-TTAACCCTGTGCCCCCTTTTTCT-3FLU 
59353 TIC 5 -AT A TTTTCT AACAGA TTCTG- 3 5 -LC-Red -AGA TCT A TTCTCT AGCTT A TTTT AAGCTC_A AC-3 p 
5-CCGTTCCCCTACAAGAAACTCT- 3 5 - CCGTAAATAAACTTTCAGACCA- 3-FLU 
59402 GIA 5 -CCGTTCCCCT ACAAGAAACTCT- 3 5 -AGA TCT A TTCTCT AGCTT A TTTT AAGCTCAAC- 3-FLU 
5 -A TA TTTTCTAACAGA TTCTG- 3 5 -LC-Red 640-TAAAAAGAAGAACTGTTCTCTGA TTC - 3 p 
59653 err 5 -TCA TCTGGCCAGAAGAGCTG- 3 5 -LC-Red 640-CAAACACCAAGTGCTCA TA CAA TT A TC- 3p 
5 -ACGGTTATAACATCAAAGAT- 3 5 -GGAAACCCATAGAAGACATTTG- 3-FLU 
Fluorescent labelled hydridization probes were synthesized by TIB MOLBIOL 
(Germany). 
A.5 CCRS Promoter Sequence 






TAGACAACAG GTTT ~rrr, ~~~ r-r•r TGGGTGGTGA GCATCTGTGT 
GGGGGTTGGG !GTGGGATAGG GGATACGGGG AGAGTGtk,~ i-J,J>.AGGGGG ~ .7,CAGGGTTAJ.. I 
TGTGAAGTCC AGGATCCCCC TCTACATTTA AAGTTGGTTT AAGTTGGCTT TAATTAATAG 
CAACTCTTAA GATAATCAGA ATTTTCTTAA CCTTT.__~~~~~~~--'--, T 
GATCTTGTAC AAATCATTTG CTTCTTGGAT AGTAATTTCT TTTACTAAAA 
I rr.:AcTAGAJ G AATGTAAATG TTCTTCTAGC TCTGATATcc TTTATTCTTT j .. ,.,. ~ ·; . ~ ,,.._ ! 







l:cG,Al-.ATJI.Jl. ;..CT~ TCAGAC o !GhGATCTA TTCTCTAGCT TATTTTAAGC TCAACT ~AAA 
AGGAAGAACT GTTCTCTGAT TCTTTTCGCC TTCAATACAC TTAATGATTT AACTCCACCC 
TCCTTCAAAA GAAACAGCAT TTCCTACTTT TATACTGTCT ATATGATTGA TTTGCACAGC 
!TCATCTGGCC AGAAG~ AGACATC -.. ;.._r-;.J-. ,,:._;._\ '" C CCGGTAAGTA 
ACCTCTCAGC TGCTTGGCCT GTTAGTTAGC TTCTGAGATG AGTAAAAGAC TTTAd~~r,;.A! 
I ;_cc ~r-:. ;._r;._;._ ~~c .=,~ ·:·1 ,le !AAACACCAAG TGCTCATACA ATTAT tTTAA AATATAATCT 
TTAAGATAAG GAAAGGGTCA CAGTTTGGAA TGAGTTTCAG ~
Fig 5 : CCR5 promoter sequence (U95626), arrows indicate the position and direction of the 
primers. Rectangles represent the position of the probes, in red are the anchor probes and 
in blue are the sensor probes. Within the sensor probes indicated in purple are the actual 
polymorphic sites, 590290/A, 59353T/C, 59356 CIT and 59653C/T. 
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APPENDIX B: TISSUE CULTURE TECHNIQUES 
B.1 Isolation of PBMC 
PBMC were isolated from approximately 20ml whole blood by Ficoll hypaque density 
gradient centrifugation. The tubes were centrifuged at 250g for 15 minutes and the 
plasma collected and stored. The huffy coat was removed and mixed with 5ml of 
phosphate buffered saline (PBS). This cell suspension was carefully layered onto 5ml 
Ficoll in a 15ml conical tube and centrifuged at 400g for 30 minutes . 
The mononuclear cells which sedimented on top of the Ficoll layer were carefully 
removed and washed twice with PBS then resuspended in 1ml medium. Viable cells were 
counted using trypan blue exclusion criteria under a haemocytometer. 
B.2 In vitro stimulation 
PBMC from 17 HEPS and 5 controls (laboratory co-workers considered to be at low risk 
for HIV-! infection), were isolated from whole blood by standard Ficoll-hypaque density 
centrifugation. The cells were stimulated with phytohemagglutinin (PHA) 5% for 
72hours in RPMI 1640 medium supplemented with 20% fetal calf serum - 100 U/ml of 
streptomycin and penicillin ( complete medium) at a density of I x IO 7 in a 15 ml flask at 
37°c . 
B.3 In vitro infection assay 
PBMC from HEPS and control subjects were plated at a density of 2 x 1 o5 cells per well 
in 96-well plates, in complete RPMI medium containing IL-2 (5%) in a volume of 100µ1. 
Cultures were inoculated with HIV-1 supernatants in a final volume of 200µ1. Virus 
replication was assessed at regular intervals (days 4,7, and 14) over a 2 week period by 
measuring the production HIV-1 p24 antigen in the culture supernatants by an ELISA 
assay. Half of the supernatant from the cultures was removed for the p24 assay, and 
replaced with fresh media containing IL-2 (5%). 
B.4 p24 ELISA 
Each well of a high binding 96 well plate was coated with 100µ1 of anti-HIV-I p24 
antibody (D7320, Aalto Bio, Ireland) and incubated over night at room temperature. 
Plates were washed twice with Tris Buffered Saline (TBS) followed by 100µ1 of 2% milk 
in TBS and incubated for 1 hour at room temperature. 
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Plates were washed with TBS and 100µ1 of culture supernatant plus l 00µ1 of I% 
Empigen was added to each well. Plates were incubated for 2 hrs at 3 7°C, after which 
they were washed thoroughly with TBS. 
To each well 100µ1 of anti-HIVl p24 antibody conjugated to alkaline phosphatase 
(EH12AP, Aalto Bio, Ireland) in 2% sheep serum (Sigma) and 0.05% Tween in TBS was 
added and incubated for 1 hour at 37°C. Plates were washed 4x with AMPAK buffer 
(Dako, Denmark) using an automated washer, followed by the addition 50µ1 substrate 
(Dako, Denmark) and incubated for an hour at room temperature. After this 50µ1 of 
amplifier (Dako, Denmark) was added for 3 minutes at room temperature and then 50µ1 
of stop solution (0.5 M HCL) was added. The optical density (OD) was read using an 
automatic plate reader at 492nm. 
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APPENDIX C: MATERIALS 
C.1 Loading buffer (lOx concentrated) 










The above mentioned ingredients were mixed with distilled water to the required volume. 
The solution was dispensed into 10ml aliquots and kept at room temperature (Ausebel, et 
al. , 1987). 




The above ingredients were dissolved in 900ml of distilled water and pH was adjusted to 
7.5. Distilled water was added to a final volume of I 000ml and the solution was 
dispensed into aliquots of 200ml. PBS was sterilized by autoclaving and stored at room 
temperature. 
C.3 Tris-acetate (T AE) Buffer 
50x concentrated: 
TRIS 





The above mentioned ingredients were mixed with distilled water to a final volume of I 
00ml, autoclaved and stored at room temperature (Sambrook, et al., 1989). 
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C.4 Trypan Blue 




The powder was dissolved in the saline solution and filtered through Whatman numberl 
paper. The dye was sterilized by filtering through a 0.2µm filter, dispensed into 2ml 
aliquots. 
C.5 Ethidium Bromide 
1 Ong Ethidium bromide 
Dissolved in 1 ml of distilled water 
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